Details of the Drug

General Information of Drug (ID: DMS8IFC)

Drug Name
Sorafenib
Synonyms
Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Carcinoma 2A00-2F9Z Approved [1]
Clear cell renal carcinoma N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Medullary thyroid gland carcinoma N.A. Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Renal cell carcinoma 2C90 Approved [2]
Thyroid cancer 2D10 Approved [1]
Hepatocellular carcinoma 2C12.02 Phase 3 [2]
Myelodysplastic syndrome 2A37 Phase 2 [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EX02: Sorafenib
L01EX: Other protein kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 464.8
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 25 - 48 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 12.29315 micromolar/kg/day [5]
Chemical Identifiers
Formula
C21H16ClF3N4O3
IUPAC Name
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
Canonical SMILES
CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChI
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChIKey
MLDQJTXFUGDVEO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
216239
ChEBI ID
CHEBI:50924
CAS Number
284461-73-0
UNII
9ZOQ3TZI87
DrugBank ID
DB00398
TTD ID
D0W5HK
VARIDT ID
DR00304
INTEDE ID
DR1500
ACDINA ID
D00635
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [6]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Modulator [7]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [7]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [8]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [9]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [15]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [16]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [14]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [16]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [17]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [18]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Protein Interaction/Cellular Processes [19]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [20]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Protein Interaction/Cellular Processes [19]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Drug Response [21]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Drug Response [21]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Gene/Protein Processing [22]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Gene/Protein Processing [23]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [20]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Gene/Protein Processing [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Adenocarcinoma
ICD Disease Classification 2D40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase Kit (KIT) DTT KIT 1.26E-09 -0.44 -0.75
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 7.27E-04 0.26 0.31
Platelet-derived growth factor receptor beta (PDGFRB) DTT PDGFRB 1.95E-31 1.69 1.65
Epidermal growth factor receptor (EGFR) DTT EGFR 5.84E-05 0.32 0.55
P-glycoprotein 1 (ABCB1) DTP P-GP 1.42E-02 -2.10E-01 -5.11E-01
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 1.94E-08 1.59E-01 6.93E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 1.07E-06 -3.94E-01 -6.94E-01
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 5.32E-02 -1.36E-01 -2.97E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 1.86E-13 4.08E-01 7.55E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 8.73E-01 1.50E-03 9.14E-03
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.90E-11 -1.06E-01 -1.42E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.26E-01 -3.16E-02 -1.31E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 2.45E-13 -2.29E+00 -1.44E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.04E-04 -9.90E-02 -3.91E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 3.3171 5.0436 2.457 5.4903
NOS-1 [Human HNSCC] GDSC1; GDSC2 -0.7109 4.5627 -1.4711 42.6321
EW-18 GDSC1; GDSC2 1.9583 5.9821 0.7355 20.6584
SK-N-MC CTRP2 1.9937 2.7738 1.9937 26.9862
ES1 GDSC1; GDSC2 2.2001 5.0491 1.408 15.8154
ES8 GDSC1; GDSC2 2.2603 4.3234 1.7926 13.2888
HuO9 GDSC2 2.4091 5.1432 1.5714 14.0491
TC-71 GDSC1; GDSC2; CCLE 2.4647 4.0027 2.1411 8.6713
CADO-ES1 GDSC2 2.5189 5.4413 1.5362 13.8665
EW-12 GDSC1; GDSC2 2.527 3.8189 2.2817 9.3353
ES6 GDSC1; GDSC2 2.5525 5.1685 1.699 12.7501
EW-11 GDSC1; GDSC2 2.5558 5.0826 1.7431 12.4682
EW-7 GDSC2 2.5924 3.6816 2.4051 8.349
EW-16 GDSC1; GDSC2 2.6369 4.4495 2.1197 9.8693
ES5 GDSC1; GDSC2 2.6913 4.2899 2.2474 8.8904
EW-3 GDSC1; GDSC2 2.7271 4.3683 2.247 8.7588
EW-22 GDSC1; GDSC2 2.8195 4.6637 2.1971 8.7307
EW-1 GDSC1; GDSC2 2.8223 4.5453 2.2565 8.3544
CAL-72 GDSC2 2.867 4.3321 2.4012 7.3025
ES7 GDSC1; GDSC2 2.9019 4.5887 2.3117 7.7318
SK-PN-DW GDSC1; GDSC2 2.9817 6.1465 1.617 11.8084
MHH-ES-1 GDSC2; CTRP2; CCLE 2.9928 4.8042 2.9531 20.4638
H-EMC-SS GDSC1; GDSC2 3.0085 6.0901 1.6686 11.4019
SK-ES-1 GDSC1; GDSC2; CTRP2; CCLE 3.0822 4.2066 3.0791 19.7447
EW-24 GDSC1; GDSC2 3.0845 4.401 2.5737 5.4764
NY GDSC2 3.1654 4.5211 2.5874 5.1267
HOS GDSC2; CTRP2; CCLE 3.205 4.6145 3.1898 18.9672
CHSA0011 GDSC2 3.213 7.3496 1.2166 13.5492
MG-63 GDSC2; CTRP2; CCLE 3.2372 4.5215 3.2277 18.7338
A-673 GDSC2; CTRP2; CCLE 3.3021 5.2252 3.229 18.5182
EW-13 GDSC1; GDSC2 3.4671 7.7265 1.2394 12.6637
CHSA0108 GDSC2 4.0065 8.1903 1.4321 10.0459
SJSA-1 GDSC1; GDSC2; CTRP2; CCLE 4.0224 6.4871 3.7027 14.611
U-CH2 GDSC2 4.0258 6.0381 2.4962 3.5009
SaOS-2 GDSC2; CTRP2; CCLE 4.0478 6.1368 3.8395 14.0333
HuO-3N1 GDSC2 4.0673 6.2811 2.408 3.9444
ES4 GDSC1; GDSC2 4.1407 5.9964 2.5898 2.7255
TC71 CTRP2 4.2368 5.9623 4.0935 12.5417
CHSA8926 GDSC2 4.4708 8.5494 1.5926 7.9789
G-292 clone A141B1 GDSC2; CTRP2 4.4875 6.2011 4.3 11.0342
CAL-78 GDSC2; CTRP2; CCLE 4.5214 6.8012 4.1282 11.5794
Hs 888.T CTRP2 4.7172 5.9371 4.6238 9.1659
Hs 822.T CTRP2 5.0693 6.1736 4.9423 6.9458
SW1353 CTRP2; CCLE 8.2922 10.759 5.1929 0.9474
U2OS GDSC2; CTRP2; CCLE 8.5683 10.5144 5.4052 0.3319
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 223 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 2.5363 3.1628 2.5363 23.3716
JK1 CTRP2 2.6533 4.0471 2.6247 17.17
JM1 GDSC1; GDSC2; CTRP2 2.1132 4.4046 2.0662 26.3483
EoL-1 GDSC1; GDSC2; CTRP2 -10.9793 -9.577 -10.9793 99.8225
MV4-11 GDSC1; GDSC2; CTRP2 -8.4004 -5.3957 -8.4004 91.6086
MOLM-13 GDSC1; GDSC2; CTRP2 -6.4836 -2.614 -6.4865 80.9088
Mono-Mac-6 GDSC1; GDSC2; CTRP2 -4.2852 8.4946 -5.9816 60.5555
ALL-PO GDSC1; GDSC2 -3.1014 4.1216 -3.9217 59.164
Mono-Mac-1 CTRP2; CCLE -1.25 9.8436 -3.2007 49.1141
SEM CTRP2 -1.0724 5.8068 -1.6588 47.8453
Kasumi-1 GDSC1; GDSC2; CTRP2 -0.864 4.7674 -1.1886 46.4317
WIL2 NS GDSC1; GDSC2 -0.7295 2.341 -0.8755 41.2064
GDM-1 GDSC1; GDSC2; CTRP2 0.4776 6.6241 -0.1985 38.8481
KMS-26 CTRP2; CCLE 0.5405 2.4134 0.5378 36.6765
NKM-1 GDSC1; GDSC2 0.5667 13.0627 -3.9996 40.8873
LAMA-84 GDSC1; GDSC2 0.6238 2.1237 0.5981 27.2057
QIMR-WIL GDSC1; GDSC2 0.7748 2.5672 0.7059 25.9128
KMOE-2 GDSC1; GDSC2 0.7824 2.2645 0.7518 25.6397
BE-13 GDSC1; GDSC2 0.9099 3.2454 0.7101 25.246
A3/Kawakami GDSC1; GDSC2; CTRP2 0.9981 2.5462 0.997 33.6228
Sc-1 GDSC1 1.0154 2.3296 0.8204 13.6252
U-698-M GDSC1; GDSC2 1.1045 4.8336 0.37 26.1565
OCI-AML-5 GDSC1; CTRP2; CCLE 1.1663 5.7793 0.7908 33.6936
ALL-SIL GDSC1; GDSC2; CTRP2; CCLE 1.174 2.9821 1.1696 32.4619
KG-1 GDSC1; GDSC2; CCLE 1.1913 4.0557 0.7618 19.7419
MY-M12 GDSC1; GDSC2 1.237 3.5821 0.9706 22.3358
NK-92MI GDSC1; GDSC2 1.2449 3.0083 1.1325 21.4267
P32/ISH GDSC1; GDSC2 1.4135 2.8293 1.35 19.4778
HL-60 GDSC1; GDSC2; CTRP2 1.4223 2.3413 1.4223 30.7929
NCO2 CCLE 1.546 2.9342 1.4307 13.0053
Ramos.2G6.4C10 GDSC1; GDSC2 1.5827 3.9791 1.2111 19.4705
DoHH2 GDSC1; GDSC2; CCLE 1.5931 3.1503 1.4792 14.943
OCI-Ly7 GDSC2 1.6018 3.7327 1.3184 18.7853
Karpas-231 GDSC1; GDSC2 1.612 2.8925 1.553 17.4628
SUP-B8 GDSC2 1.6403 3.8643 1.3144 18.6387
SUP-M2 GDSC1; GDSC2; CTRP2; CCLE 1.6818 2.7829 1.6817 29.0645
EB1 CTRP2; CCLE 1.6841 2.7845 1.6839 29.0494
Pfeiffer CTRP2; CCLE 1.7109 2.3038 1.7109 28.8703
SIG-M5 GDSC1; GDSC2; CTRP2; CCLE 1.7207 3.5245 1.7122 28.8334
SU-DHL-5 GDSC2 1.7402 7.7819 -0.3327 26.9106
BALL-1 GDSC1; GDSC2 1.7431 3.8539 1.4291 17.5462
KE-37 GDSC1; GDSC2; CTRP2 1.7482 2.4602 1.7482 28.6219
LP-1 GDSC1; GDSC2; CTRP2; CCLE 1.7529 2.6742 1.7528 28.5908
KO52 CTRP2; CCLE 1.7542 4.0651 1.7192 28.6993
697 GDSC1; GDSC2; CTRP2; CCLE 1.7719 2.5145 1.7719 28.464
Farage GDSC1; GDSC2 1.7783 3.508 1.583 16.531
JSC-1 GDSC2 1.8048 3.6997 1.5496 16.5992
Ku812 GDSC1; GDSC2; CTRP2; CCLE 1.8137 2.8981 1.8135 28.1863
BL-41 GDSC1; GDSC2; CCLE 1.8206 2.6395 1.8076 12.6018
SU-DHL-16 GDSC1; GDSC2 1.8228 2.6062 1.8123 15.0966
Jiyoye GDSC1; GDSC2 1.8268 3.3931 1.6703 15.8318
BC-3 GDSC1; GDSC2 1.8279 3.4791 1.646 15.9607
K-562 GDSC1; GDSC2; CTRP2 1.8433 2.9997 1.843 27.9893
CRO-AP2 GDSC1; GDSC2 1.8444 2.8929 1.8031 15.0386
GA-10 GDSC1; GDSC2; CTRP2 1.8449 2.5293 1.8449 27.9777
Karpas-45 GDSC1; GDSC2 1.8462 2.7851 1.82 14.9423
EM-2 GDSC1; GDSC2; CTRP2; CCLE 1.8933 3.6201 1.8853 27.682
KMS-11 GDSC2; CTRP2; CCLE 1.9013 4.6615 1.8117 27.9042
MOLT-16 GDSC1; GDSC2; CTRP2; CCLE 1.9073 3.293 1.9055 27.5681
ML-2 GDSC1; GDSC2 1.9138 3.7422 1.6529 15.5414
HAL-01 GDSC1; GDSC2 1.9195 3.5436 1.7256 15.1101
KOPN-8 GDSC2 1.9347 3.4235 1.7791 14.7464
MEG-01 GDSC1; GDSC2; CCLE 1.9354 3.8406 1.641 12.9216
DB GDSC1; GDSC2; CTRP2 1.9458 3.6173 1.9389 27.3287
OCI-AML-3 GDSC1; GDSC2; CTRP2 1.9502 3.6878 1.9413 27.306
OPM-2 GDSC1; GDSC2; CTRP2; CCLE 1.9735 2.8653 1.9735 27.1208
A4/Fukuda GDSC1; GDSC2; CTRP2 1.9747 2.9486 1.9746 27.1133
AML-193 CTRP2 1.9839 3.1264 1.9835 27.0528
LC4-1 GDSC1; GDSC2 1.9864 3.7307 1.7354 14.7608
ME1 GDSC1; GDSC2 1.9872 2.9973 1.9393 13.641
DEL GDSC1; GDSC2; CTRP2; CCLE 1.9873 3.0376 1.9871 27.0295
Peer CTRP2 1.9914 3.8132 1.979 27.0429
MOLT-3 CTRP2 1.9961 2.9751 1.996 26.9706
RC-K8 GDSC1; GDSC2 2.0292 4.1189 1.6349 15.1535
VL51 GDSC1; GDSC2 2.0512 3.1627 1.9751 13.1482
CESS GDSC1; GDSC2 2.0565 3.4477 1.9046 13.5062
L-540 GDSC1; GDSC2; CTRP2 2.0716 4.0675 2.049 26.5429
BC-1 GDSC1; GDSC2 2.0835 3.2392 1.9921 12.9063
PL-21 GDSC1; GDSC2 2.1234 3.9179 1.8138 13.7271
VAL GDSC1; GDSC2 2.1365 3.7478 1.8912 13.2294
KM-H2 GDSC1; GDSC2; CTRP2 2.1392 5.307 1.9588 26.6322
KMS-34 CTRP2; CCLE 2.1618 2.9998 2.1618 25.8665
ST486 GDSC1; GDSC2; CTRP2 2.1635 3.2568 2.1631 25.8562
MHH-PREB-1 GDSC1; GDSC2 2.2021 4.2332 1.7702 13.6546
KMS-12-BM GDSC1; GDSC2; CTRP2; CCLE 2.205 3.4609 2.2037 25.5829
RPMI-8866 GDSC1 2.2113 4.4162 0.9632 7.4398
WSU-DLCL2 GDSC1; GDSC2; CTRP2 2.2233 2.9541 2.2233 25.4569
ATN-1 GDSC1; GDSC2 2.2247 3.6367 2.0259 12.0852
SU-DHL-1 GDSC1; GDSC2; CTRP2 2.2326 3.6011 2.2299 25.4037
MN-60 GDSC1; GDSC2 2.234 3.63 2.0382 11.9755
KMS-21-BM CTRP2 2.2725 4.1024 2.2547 25.1883
P30/OHK GDSC1; GDSC2 2.2731 3.7797 2.0263 11.8743
Daudi GDSC1; GDSC2; CTRP2 2.2748 3.3081 2.2745 25.1144
Namalwa GDSC1; GDSC2; CTRP2 2.285 3.4372 2.2842 25.0485
BL-70 CTRP2; CCLE 2.2904 3.4678 2.2894 25.0129
CTB-1 GDSC1; GDSC2 2.3107 4.1362 1.9243 12.3095
CML-T1 GDSC2; CTRP2 2.3194 3.4765 2.3185 24.8196
BV-173 GDSC1; GDSC2; CTRP2 2.3454 5.437 2.1558 25.2932
WSU-NHL GDSC1; GDSC2 2.3654 3.464 2.2361 10.2897
HC-1 GDSC1; GDSC2 2.3661 3.1337 2.3235 9.8125
MHH-CALL-2 GDSC2 2.3692 4.0984 2.0013 11.6203
JeKo-1 GDSC2; CTRP2 2.372 3.1457 2.372 24.466
KMS-18 CTRP2 2.3961 4.1917 2.3775 24.368
Mino CTRP2; CCLE 2.4075 2.9558 2.4075 24.2294
L-1236 GDSC1; GDSC2 2.4162 3.9638 2.1063 10.8138
YT GDSC1; GDSC2 2.4403 3.0394 2.4196 8.9535
PF-382 GDSC1; GDSC2; CTRP2 2.4408 4.616 2.3901 24.1787
JURL-MK1 GDSC1; CTRP2 2.4495 3.7856 2.4462 23.9607
HT GDSC1; GDSC2; CTRP2; CCLE 2.4521 3.4267 2.4518 23.9335
P12-Ichikawa GDSC2; CTRP2; CCLE 2.4534 3.4475 2.4531 23.9247
F-36P CTRP2; CCLE 2.474 4.4498 2.4407 23.8986
HEL 92.1.7 CTRP2; CCLE 2.4832 3.6873 2.4815 23.7308
TF-1 CTRP2 2.4835 3.9745 2.4764 23.7468
DND-41 GDSC1; GDSC2; CTRP2 2.5116 3.7843 2.509 23.5449
RPMI-8226 GDSC1; GDSC2; CTRP2 2.5141 4.6928 2.4593 23.7043
L-428 GDSC1; GDSC2; CTRP2; CCLE 2.5264 3.7214 2.5248 23.4428
KMS-20 CTRP2 2.5326 3.7561 2.5306 23.4027
CTV-1 GDSC1; GDSC2 2.5366 3.7467 2.3204 9.0713
MLMA GDSC1; GDSC2 2.5373 3.7776 2.3091 9.1337
CCRF-CEM GDSC1; GDSC2 2.5544 4.2641 2.1208 10.1767
RL GDSC1; GDSC2; CTRP2 2.5566 3.3963 2.5565 23.2367
CMK-86 CCLE 2.5567 3.8248 2.1779 5.6957
EB2 GDSC1; GDSC2; CCLE 2.5619 3.5968 2.404 7.0667
ARH-77 GDSC1; GDSC2 2.5691 3.7214 2.365 8.678
CA46 GDSC1; GDSC2; CTRP2 2.5988 4.9731 2.5132 23.2455
M-07e CTRP2 2.6012 4.3522 2.5803 23.0091
Loucy GDSC1; GDSC2 2.6323 3.8771 2.3688 8.395
DG-75 GDSC1; GDSC2 2.6336 3.7783 2.4108 8.1439
THP-1 GDSC1; GDSC2; CTRP2 2.6451 4.3397 2.6266 22.7085
HH [Human lymphoma] GDSC1; GDSC2; CTRP2; CCLE 2.6525 4.6615 2.6088 22.7448
MEC-1 CCLE 2.6568 4.2323 2.0787 5.9172
MOLM-6 CTRP2 2.6683 4.7142 2.62 22.6551
BONNA-12 GDSC2 2.6707 4.0278 2.3441 8.3878
BDCM CTRP2; CCLE 2.6811 3.6624 2.6807 22.4081
KYO-1 CTRP2 2.6834 3.9647 2.6798 22.4035
KY821 GDSC1; GDSC2 2.702 3.6376 2.5391 7.1162
GR-ST GDSC1; GDSC2 2.703 3.8429 2.457 7.5904
IM-9 GDSC1; GDSC2 2.7048 3.3979 2.6263 6.6115
JVM-2 GDSC1; GDSC2 2.7256 4.4526 2.2062 9.0134
NALM-6 GDSC1; GDSC2; CTRP2 2.7313 4.0047 2.7275 22.0848
Hs 611.T CTRP2 2.7322 4.6219 2.6964 22.187
KE-97 CTRP2; CCLE 2.7341 3.9978 2.7304 22.0659
Hs 445 GDSC1; GDSC2 2.7353 4.4751 2.2051 8.9842
SCC-3 GDSC1; GDSC2 2.7499 4.0729 2.405 7.7155
SU-DHL-4 GDSC1; GDSC2; CTRP2; CCLE 2.7577 5.3994 2.4436 17.5153
P31/FUJ GDSC1; GDSC2; CTRP2; CCLE 2.7604 4.0734 2.7556 21.8945
NU-DUL-1 GDSC1; GDSC2; CTRP2 2.7731 4.7319 2.7288 21.9433
SET-2 CTRP2 2.8006 3.9875 2.7979 21.6197
MOLP-8 GDSC1; GDSC2; CTRP2; CCLE 2.8097 5.1174 2.7173 21.8646
MOLT-4 GDSC1; GDSC2 2.8136 4.0191 2.4936 6.938
SUP-HD1 GDSC1; GDSC2; CTRP2 2.8326 5.3495 2.7016 21.8463
SUP-B15 GDSC1; GDSC2; CTRP2 2.8328 5.4905 2.6737 21.9432
EJM GDSC1; GDSC2; CTRP2 2.8616 5.076 2.7793 21.484
RPMI-8402 GDSC1; GDSC2; CTRP2; CCLE 2.8704 3.8467 2.8697 21.1478
Kasumi-2 CTRP2; CCLE 2.9261 3.6778 2.926 20.7746
SK-MM-2 GDSC1; GDSC2; CTRP2; CCLE 2.9386 4.8931 2.8861 20.8687
SR GDSC1; GDSC2; CTRP2 2.9577 4.6271 2.932 20.6502
OCI-Ly3 CTRP2 2.9585 5.6904 2.7664 21.2227
MOLM-16 GDSC2; CTRP2 2.9646 4.5927 2.9418 20.5944
HD-MY-Z CTRP2; CCLE 3.0026 4.6414 2.9778 20.3482
CMK CTRP2 3.0175 4.8481 2.9745 20.3107
OCI-M1 GDSC1; GDSC2; CTRP2 3.0223 4.606 3.0008 20.2059
JJN-3 GDSC1; GDSC2; CTRP2 3.0506 5.245 2.9556 20.2692
RCH-ACV GDSC2; CTRP2 3.0627 4.9458 3.0114 20.0377
Karpas-1106P GDSC2 3.0768 4.5429 2.4968 5.9832
KCL-22 GDSC1; GDSC2; CTRP2; CCLE 3.0834 5.2787 2.9852 20.0616
H9 GDSC1; GDSC2 3.1345 5.5595 2.0433 8.6558
Karpas-422 GDSC1; GDSC2; CTRP2; CCLE 3.1434 4.411 3.1359 19.3518
KMS-28BM CTRP2 3.1539 5.1517 3.0812 19.5042
NCI-H929 GDSC2; CTRP2 3.1706 4.0203 3.1701 19.1472
RS4;11 GDSC1; GDSC2; CTRP2 3.1707 4.8677 3.1341 19.2684
Ri-1 CTRP2 3.1712 8.4594 2.0308 23.283
TUR GDSC1; GDSC2 3.1805 4.6352 2.544 5.3529
TK [Human B-cell lymphoma] GDSC1; GDSC2 3.2084 5.0984 2.3374 6.5715
ROS-50 GDSC1; GDSC2 3.2142 6.5521 1.6162 11.0939
SKM-1 GDSC1; GDSC2; CTRP2 3.2172 5.1101 3.1548 19.0468
KMS-27 CTRP2 3.2541 4.7981 3.228 18.6771
U-937 CTRP2; CCLE 3.3519 5.2416 3.2799 18.1827
JM-1 CCLE 3.4481 5.2182 2.2385 3.1361
HDLM-2 GDSC1; GDSC2; CTRP2 3.4654 5.222 3.4043 17.389
PL21 CTRP2 3.4925 5.3202 3.4185 17.2529
U266B1 GDSC1; GDSC2; CTRP2 3.4994 4.7969 3.4837 17.0078
SUP-T11 CTRP2 3.5819 5.1118 3.5425 16.5387
SUP-T1 GDSC1; GDSC2; CTRP2; CCLE 3.5887 4.5333 3.5859 16.3694
REC-1 CTRP2 3.64 6.3425 3.3333 17.1035
MOTN-1 CTRP2 3.6945 6.213 3.4319 16.5798
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 3.7112 5.7466 3.5728 16.0226
Granta-519 GDSC1; GDSC2; CTRP2; CCLE 3.7961 5.7231 3.6705 15.4119
NU-DHL-1 CTRP2 3.8328 5.1383 3.8048 14.8282
L-363 GDSC1; GDSC2; CTRP2; CCLE 3.8787 5.9339 3.7101 15.0151
Ki-JK CTRP2 3.9059 6.2797 3.6424 15.178
SU-DHL-8 GDSC1; GDSC2; CTRP2; CCLE 3.9443 10.7461 1.2318 19.25
Karpas-620 GDSC2; CTRP2; CCLE 4.2088 6.8684 3.7683 13.8288
RPMI-6666 GDSC1; GDSC2; CTRP2 4.2602 6.4491 3.9735 12.9101
Toledo CTRP2; CCLE 4.2757 5.3994 4.2445 11.889
HPB-ALL CTRP2 4.373 5.9342 4.2493 11.565
OCI-Ly19 GDSC1; GDSC2; CTRP2 4.4841 7.5428 3.7853 13.011
HuT 78 CCLE 4.5219 7.0736 2.0481 2.3812
Ci-1 CTRP2; CCLE 4.5903 6.8151 4.1962 11.1271
MOLP-2 CTRP2 5.0004 6.4459 4.7748 7.7709
KMM-1 CTRP2; CCLE 5.0907 9.2971 3.568 12.4007
MHH-CALL-3 CTRP2 5.2819 6.4215 5.0857 5.7949
MC116 GDSC1; GDSC2; CTRP2; CCLE 5.8022 11.7875 2.2817 10.8741
MJ CCLE 5.9016 8.2506 2.2241 0.589
SU-DHL-10 GDSC2; CTRP2; CCLE 6.5395 7.9984 4.5501 0.4741
P3HR-1 CTRP2; CCLE 6.7178 11.2534 3.1992 5.412
JVM-3 GDSC1; GDSC2; CTRP2; CCLE 6.9399 11.0024 4.2663 5.9105
Jurkat GDSC2; CTRP2; CCLE 7.4773 9.6147 5.2645 1.3376
KHM-1B CTRP2; CCLE 7.5431 9.7671 5.2338 1.3821
NB4 GDSC1; GDSC2; CTRP2 7.7277 8.9348 5.6509 0.167
HEL GDSC1; GDSC2; CTRP2 7.766 8.7628 5.7249 0.0672
NOMO-1 GDSC1; GDSC2; CTRP2 7.7741 9.1184 5.6025 0.2343
EHEB CTRP2 7.7988 10.5619 5.0258 1.8549
Reh GDSC1; GDSC2; CTRP2; CCLE 7.8167 9.2143 5.5842 0.2535
Karpas-299 GDSC1; GDSC2; CTRP2; CCLE 7.904 9.5911 5.4788 0.435
AMO1 GDSC1; GDSC2; CTRP2; CCLE 7.9422 9.2197 5.6304 0.1453
MOLT-13 GDSC1; GDSC2; CTRP2 7.9707 9.5835 5.5095 0.3423
Raji GDSC1; GDSC2; CTRP2; CCLE 8.0006 9.3466 5.6073 0.1642
SU-DHL-6 GDSC1; GDSC2; CTRP2; CCLE 8.1485 10.4152 5.2643 0.8405
MM1.S GDSC2; CTRP2 8.2598 9.7686 5.5549 0.1781
OCI-AML-2 GDSC1; GDSC2; CTRP2; CCLE 8.2743 9.5947 5.6205 0.0968
MHH-CALL-4 GDSC2; CTRP2 8.3606 18.5177 1.6169 13.8709
OCI-Ly10 CTRP2; CCLE 8.366 10.3642 5.3793 0.4542
⏷ Show the Full List of 223 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 2.8592 4.2612 2.8506 21.2492
TE15 CTRP2 4.236 6.7363 3.8465 13.4558
TE-5 GDSC1; GDSC2; CTRP2; CCLE 2.289 4.5924 2.2322 25.2107
KYSE-150 GDSC2; CTRP2; CCLE 2.7189 3.3957 2.7188 22.1552
TE-6 GDSC1; GDSC2 2.7883 3.9252 2.5098 6.9382
T.T GDSC2 2.8605 4.1531 2.4789 6.8504
EC-GI-10 GDSC1; GDSC2; CTRP2 2.8613 4.5384 2.8381 21.2844
KYSE-270 GDSC2 2.9922 5.9291 1.7343 11.0441
KYSE-180 GDSC2; CTRP2; CCLE 3.0343 4.6484 3.0103 20.1341
KYSE-450 GDSC2; CTRP2; CCLE 3.1592 4.9657 3.1114 19.3829
KYSE-410 GDSC2; CTRP2; CCLE 3.358 5.6051 3.2199 18.3726
OE21 GDSC2; CTRP2; CCLE 3.374 4.9694 3.3382 17.9115
TE-8 GDSC1; GDSC2 3.5401 5.4624 2.4276 5.0592
TE-11 GDSC2; CTRP2; CCLE 3.6346 5.2171 3.5856 16.2205
KYSE-30 CTRP2; CCLE 3.7291 5.2528 3.6816 15.5856
TE-9 GDSC1; GDSC2; CTRP2; CCLE 3.7514 5.8993 3.5801 15.8718
TE-14 CTRP2 3.7656 5.6263 3.6579 15.5518
KYSE-140 GDSC2; CTRP2; CCLE 3.7673 7.2328 3.1574 17.3936
KYSE-510 GDSC2; CTRP2; CCLE 3.7797 5.721 3.6531 15.5243
KYSE-520 GDSC2; CTRP2; CCLE 3.8045 6.1241 3.5777 15.7184
TE-4 GDSC2; CTRP2 4.001 6.1749 3.7774 14.4
TE-15 GDSC1; CCLE 6.2316 8.2124 2.3627 0.2119
OE33 GDSC2; CTRP2; CCLE 7.2717 11.6946 4.1652 5.8168
TE-1 GDSC1; GDSC2; CTRP2; CCLE 7.9839 9.9572 5.3715 0.6532
TE-10 GDSC1; GDSC2; CTRP2 8.181 13.0545 4.1197 4.7702
OE19 GDSC2; CTRP2 8.3433 16.5152 2.579 10.4469
COLO 680N GDSC2; CTRP2 8.4427 11.7768 4.8439 1.8924
KYSE-70 GDSC2; CTRP2; CCLE 8.7802 10.2854 5.5633 0.0834
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 5.6052 8.6423 4.3634 7.9614
PaTu 8988t GDSC2; CTRP2 2.5341 5.6689 2.3091 24.1623
KP-4 GDSC2; CTRP2; CCLE 2.6605 4.2186 2.6486 22.5841
KP-1N GDSC2; CCLE 2.882 4.7534 2.2131 7.0071
MIA PaCa-2 GDSC2; CTRP2; CCLE 3.0576 5.0428 2.9937 20.1151
L3.3 CTRP2; CCLE 3.0788 4.8714 3.0368 19.8989
PSN1 GDSC1; GDSC2; CTRP2; CCLE 3.1114 4.9744 3.0596 19.7152
PL4 GDSC2 3.1498 4.8125 2.4287 6.1548
KP-1NL CCLE 3.2146 5.5544 1.8969 5.4641
PK-1 CCLE 3.2541 4.5683 2.4162 2.5844
QGP-1 GDSC2; CCLE 3.2663 6.4576 1.7075 8.6447
KP-2 GDSC2; CTRP2; CCLE 3.2675 5.086 3.2117 18.6892
HuP-T4 GDSC2; CTRP2; CCLE 3.3491 4.99 3.3097 18.0896
Hs 766T GDSC2; CTRP2; CCLE 3.3814 5.3643 3.2917 18.0476
DAN-G GDSC2; CTRP2 3.5704 6.309 3.2678 17.5505
SU.86.86 GDSC2; CTRP2; CCLE 3.6307 5.0101 3.6044 16.1689
MZ-PC-1 GDSC1; GDSC2 3.6926 7.5462 1.5102 10.3535
BxPC-3 GDSC2; CTRP2; CCLE 3.7228 5.9043 3.5477 16.0758
KP-3 GDSC2; CTRP2; CCLE 3.8199 5.7441 3.6916 15.2628
PaTu 8988s CTRP2 3.9131 6.0907 3.7057 14.9258
Panc 03.27 GDSC2; CTRP2; CCLE 3.9487 6.7457 3.5336 15.4567
Capan-2 GDSC2; CTRP2; CCLE 3.9534 5.9393 3.7903 14.4984
AsPC-1 GDSC2; CTRP2; CCLE 4.0056 7.2155 3.4178 15.7348
Capan-1 GDSC2; CTRP2 4.0367 6.757 3.6245 14.8622
Panc 10.05 GDSC2; CTRP2; CCLE 4.0641 6.1154 3.8634 13.8973
Panc 08.13 GDSC2 4.2676 6.8926 2.2498 4.4638
HuP-T3 GDSC2; CTRP2; CCLE 4.3841 6.5703 4.0657 12.2062
SNU-410 CTRP2 4.4437 9.1151 3.0326 16.1047
Panc 04.03 GDSC2; CTRP2; CCLE 4.5967 7.4857 3.9263 12.159
SW1990 GDSC2; CTRP2; CCLE 4.6553 6.6649 4.3231 10.4606
PaTu 8902 GDSC2; CTRP2; CCLE 4.7053 6.0127 4.5915 9.3182
KCI-MOH1 CCLE 4.8927 7.4858 2.0689 1.8574
Panc 02.03 GDSC2; CTRP2; CCLE 5.2583 8.668 4.0311 10.1118
PL45 CCLE 6.6469 8.7699 2.3192 0.1883
PK-45H CTRP2; CCLE 6.6784 9.7739 4.678 4.6293
SNU-213 CTRP2 7.3267 11.8433 4.1316 5.8716
YAPC GDSC2; CTRP2 7.8778 9.2574 5.5925 0.2197
Panc 05.04 CTRP2 7.9016 9.848 5.3775 0.684
PK-59 CTRP2; CCLE 7.9332 11.1737 4.8302 2.409
TCC-Pan2 CTRP2 7.9418 9.0924 5.6745 0.0919
CFPAC-1 GDSC2; CTRP2 8.0676 12.3818 4.3611 3.9896
SUIT-2 GDSC2; CTRP2; CCLE 8.443 9.7884 5.6139 0.0803
HPAC GDSC2; CTRP2; CCLE 8.5872 10.2938 5.4915 0.1923
HPAF-II GDSC2; CTRP2; CCLE 8.8579 10.514 5.513 0.1188
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 79 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 3.3033 7.0874 2.715 20.3786
SH-4 GDSC1; GDSC2 -0.0999 3.6663 -0.5118 36.155
LB2518-MEL GDSC1; GDSC2 0.6789 2.7998 0.5615 27.1249
HMV-II GDSC2 0.7021 7.5225 -1.2242 34.638
A-388 GDSC1; GDSC2 1.2754 3.8441 0.9268 22.403
WM35 GDSC2 1.7684 4.6434 1.1452 19.0641
CP50-MEL-B GDSC2 1.9047 4.1808 1.4783 16.5773
MZ-MEL-7 GDSC1; GDSC2 1.9756 3.7152 1.7291 14.8431
GAK GDSC1; GDSC2 1.9977 3.1253 1.9253 13.6653
G-mel GDSC2 2.1565 3.7215 1.9222 12.9667
SK-MEL-1 GDSC1; GDSC2; CTRP2 2.2278 4.2247 2.2009 25.5168
COLO 792 GDSC2; CTRP2 2.3671 3.0463 2.3671 24.4989
DJM-1 GDSC1; GDSC2 2.3851 4.6487 1.7763 12.8991
WM266-4 CTRP2; CCLE 2.4776 3.0854 2.4776 23.7627
MZ-MEL-2 GDSC1; GDSC2 2.4995 4.149 2.115 10.4266
SK-MEL-28 GDSC2; CTRP2 2.617 2.9849 2.617 22.834
CP66-MEL GDSC1; GDSC2 2.6973 4.3896 2.2075 9.1105
HMCB CTRP2; CCLE 2.7055 3.6303 2.7052 22.2451
SK-MEL-5 GDSC2; CTRP2; CCLE 2.7988 3.4925 2.7988 21.6225
Malme-3M CTRP2; CCLE 2.8672 4.7167 2.8295 21.294
Hs 944.T CTRP2; CCLE 2.9237 4.7632 2.8843 20.9233
A-431 GDSC2 2.936 5.0395 2.1236 8.7888
CJM [Human melanoma] CTRP2 2.9404 3.6667 2.9403 20.6797
M14 GDSC2 2.9661 3.9702 2.6685 5.3028
COLO 829 GDSC1; GDSC2; CTRP2 3.0162 5.3448 2.901 20.5685
LB373-MEL-D GDSC1; GDSC2 3.026 5.3224 2.0655 8.8586
HT-144 GDSC1; GDSC2; CTRP2; CCLE 3.0671 5.0488 3.003 20.0522
IPC-298 GDSC2; CTRP2; CCLE 3.086 4.2279 3.0825 19.7212
COLO 679 GDSC2; CCLE 3.105 4.1162 2.7321 3.6786
WM88 CTRP2; CCLE 3.1126 4.8027 3.0793 19.6442
451Lu GDSC2 3.1609 5.519 2.0865 8.3023
MMAc-SF GDSC1; GDSC2 3.1623 4.7711 2.4603 5.9378
SK-MEL-2 GDSC1; GDSC2; CCLE 3.1712 3.8447 2.9264 2.4817
LOX-IMVI GDSC1; GDSC2; CTRP2; CCLE 3.2377 5.1431 3.172 18.9216
Hs 938.T GDSC2; CCLE 3.2493 5.1037 2.3698 5.1988
MeWo GDSC2; CTRP2; CCLE 3.3263 5.0728 3.2759 18.2791
UACC-62 GDSC2; CTRP2; CCLE 3.3401 3.8886 3.34 18.0167
COLO 783 GDSC2 3.3477 5.9707 2.019 8.172
WM278 GDSC2 3.3818 7.4032 1.331 12.3559
VMRC-MELG GDSC2 3.3836 5.0838 2.4919 5.0786
Hs 940.T GDSC2 3.4362 5.3321 2.4104 5.4478
WM115 GDSC2; CTRP2; CCLE 3.4767 4.5766 3.4708 17.1262
Mel Ho GDSC2; CTRP2; CCLE 3.4887 4.845 3.4693 17.0916
SK-MEL-30 GDSC2; CTRP2; CCLE 3.4946 6.3156 3.1832 18.0868
CHL-1 GDSC2; CCLE 3.5067 4.859 2.7014 2.851
IST-MEL1 GDSC1; GDSC2 3.519 7.2675 1.5108 10.8625
RVH-421 GDSC2; CTRP2; CCLE 3.8382 5.5961 3.7426 15.026
RPMI-7951 GDSC2; CTRP2; CCLE 3.848 5.0522 3.8284 14.6987
WT2-iPS GDSC2; CTRP2; CCLE 3.8739 5.7223 3.7552 14.8693
IGR-1 GDSC2; CTRP2 3.925 6.201 3.6869 14.9584
WM983B CTRP2; CCLE 4.039 6.7513 3.6289 14.8391
SK-MEL-24 GDSC2; CTRP2; CCLE 4.1924 6.0581 4.0195 12.9432
UACC-257 GDSC1; GDSC2; CTRP2; CCLE 4.2275 7.2139 3.6536 14.2157
SK-MEL-31 GDSC2; CTRP2; CCLE 4.2341 6.3781 3.9685 13.0051
Mel JuSo GDSC2; CTRP2 4.3279 7.1353 3.7913 13.4088
WM1552C GDSC2 4.4192 6.2475 2.6407 1.9791
IGR-37 GDSC2; CTRP2; CCLE 4.5754 6.3023 4.364 10.5381
A2058 GDSC2; CTRP2; CCLE 4.6138 6.432 4.3625 10.4312
Hs 294T CTRP2; CCLE 4.6711 5.8155 4.6014 9.3891
Hs 839.T CTRP2 4.6711 13.1534 1.2892 22.0654
Hs 934.T CTRP2 4.6957 6.292 4.4981 9.688
SK-MEL-3 GDSC2; CTRP2 4.815 9.2914 3.3094 14.0963
SF8657 CCLE 4.9304 7.142 2.2309 1.1851
IGR-39 CTRP2; CCLE 5.0648 7.7856 4.2656 9.6105
COLO 741 CCLE 5.1437 7.0189 2.3745 0.5717
Hs 688(A).T CTRP2 5.2381 6.0672 5.1581 5.6522
A101D GDSC1; GDSC2; CTRP2 5.465 8.6512 4.2314 8.8176
COLO 800 GDSC1; GDSC2; CTRP2 5.7796 11.0788 3.3033 12.0079
Hs 895.T CTRP2; CCLE 6.0822 11.7215 3.2373 11.6781
Hs 695T CCLE 7.1166 10.2362 1.9773 0.6533
K029AX CTRP2; CCLE 7.4337 13.7635 3.2725 9.1634
Hs 936.T CTRP2; CCLE 7.8696 8.8386 5.7352 0.0465
Hs 852.T CTRP2; CCLE 7.8748 9.5399 5.486 0.432
WM1799 CTRP2; CCLE 7.9022 9.5286 5.5019 0.3853
WM793 GDSC2; CTRP2; CCLE 8.1461 9.7069 5.5338 0.2394
MDA-MB-435S CTRP2; CCLE 8.2098 9.5229 5.6222 0.1049
A-375 GDSC2; CTRP2; CCLE 8.258 9.6623 5.5914 0.1313
G-361 GDSC2; CTRP2; CCLE 8.5007 10.1501 5.51 0.1862
EquiPSC Line K2 GDSC2 2.3683 7.5174 0.3847 21.0712
⏷ Show the Full List of 79 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-50 GDSC2 2.4272 4.9186 1.6943 13.2363
TE-12 GDSC1; GDSC2 2.5847 5.6427 1.5017 13.8452
KYSE-220 GDSC2 2.7961 3.9337 2.514 6.8825
OACM5.1 C GDSC2 3.0373 5.8969 1.7902 10.5509
OACP4 C GDSC2 3.1676 4.4347 2.6322 4.8377
ESO-51 GDSC2 3.2019 4.8572 2.4521 5.8662
HCE-4 GDSC2 3.372 5.6403 2.2042 6.9322
KYAE-1 GDSC2 3.5175 5.912 2.186 6.642
SK-GT-4 GDSC2 3.5697 5.2928 2.5345 4.3099
ESO-26 GDSC2 3.5751 5.2159 2.5768 4.0311
FLO-1 GDSC2 3.6836 5.4287 2.5526 3.9146
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2; CTRP2 2.602 5.0759 2.5009 23.2778
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SJNB-14 GDSC1; GDSC2 0.435 1.1077 0.435 28.9708
SJNB-6 GDSC1; GDSC2 0.9792 4.072 0.5272 25.8958
TGW GDSC1; GDSC2 1.7093 2.4855 1.702 16.2197
SJNB-7 GDSC1; GDSC2 1.8481 8.5007 -0.5791 27.5608
SJNB-13 GDSC1; GDSC2 1.8804 3.4588 1.7093 15.3752
SK-N-MC-IXC GDSC2 1.9915 6.2672 0.6335 21.1006
CHP-126 GDSC1; GDSC2 2.0059 3.8192 1.7247 14.7366
LA-N-6 GDSC1; GDSC2 2.0075 3.4116 1.862 13.9622
GOTO GDSC1; GDSC2 2.1021 3.9312 1.7859 13.9772
CHP-134 GDSC2 2.1849 3.113 2.1312 11.6883
NB(TU)1 GDSC1; GDSC2 2.2306 3.1765 2.1673 11.2807
SK-N-DZ GDSC1; GDSC2; CTRP2; CCLE 2.2493 5.1915 2.1005 25.7907
SJNB-5 GDSC1; GDSC2 2.3601 3.905 2.0707 11.2522
SK-N-FI GDSC1; GDSC2; CTRP2; CCLE 2.4045 3.419 2.4042 24.2506
KP-N-RT-BM-1 GDSC2 2.4801 4.2864 2.0351 10.9787
SK-N-BE(2)-M17 GDSC1; GDSC2 2.5304 4.0107 2.2063 9.7631
SJNB-12 GDSC1; GDSC2 2.5564 3.7656 2.3341 8.9095
IMR-32 CTRP2; CCLE 2.557 3.0428 2.557 23.2338
NB69 GDSC1; GDSC2 2.559 3.5301 2.4244 8.3829
SiMa GDSC1; GDSC2; CCLE 2.6559 3.9055 2.3815 6.8497
KP-N-YS GDSC1; GDSC2 2.6563 5.3167 1.7271 12.2098
IMR-5 GDSC1; GDSC2 2.6904 3.3964 2.6111 6.76
NH-12 GDSC1; GDSC2 2.7579 4.1609 2.3732 7.8769
MHH-NB-11 GDSC1; GDSC2; CTRP2 2.8941 4.244 2.8868 21.0123
CHP-212 GDSC2; CTRP2; CCLE 2.898 4.3116 2.8884 20.9941
SJNB-17 GDSC1; GDSC2 2.9569 4.5809 2.3673 7.1965
GI-ME-N GDSC1; GDSC2 2.9621 4.5168 2.4034 6.954
SK-N-SH GDSC2; CTRP2; CCLE 2.9852 5.323 2.8715 20.7695
NH-6 CTRP2 3.1153 4.7841 3.0838 19.6201
SK-N-BE(2) CTRP2; CCLE 3.2952 4.7507 3.2747 18.3843
Kelly GDSC1; GDSC2; CTRP2; CCLE 3.3332 4.319 3.3311 18.0693
SK-N-AS GDSC2; CTRP2; CCLE 3.5518 5.5351 3.4443 16.9748
NB1 GDSC1; GDSC2; CTRP2 3.6036 5.1693 3.5587 16.413
SJNB-10 GDSC1; GDSC2 3.6052 5.7887 2.3159 5.5919
KP-N-YN GDSC1; GDSC2; CTRP2 4.4742 6.3714 4.2315 11.326
KP-N-SI9s CTRP2; CCLE 8.1682 11.4127 4.8553 2.095
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 2.9332 4.7462 2.896 20.8528
HuCC-T1 GDSC2; CTRP2; CCLE 3.175 5.0917 3.1123 19.329
SNU-478 CTRP2 3.5877 5.0948 3.5506 16.4921
HuH-28 CTRP2 4.0829 5.035 4.0736 13.0989
SNU-308 CTRP2 4.6938 6.3941 4.462 9.8277
SNU-869 CTRP2 5.0517 8.1628 4.0759 10.413
SNU-1196 CTRP2 8.3716 9.8286 5.5749 0.1302
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 92 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OCUB-M GDSC1; GDSC2 1.375 2.7929 1.3147 19.7776
DU4475 GDSC1; GDSC2; CTRP2 1.4946 2.1649 1.4946 30.3116
HCC2218 GDSC1; GDSC2; CTRP2 1.6325 3.9755 1.599 29.5048
HCC2157 GDSC1; GDSC2 1.8184 3.2486 1.7005 15.7067
MRK-nu-1 GDSC1; GDSC2 1.8492 3.3712 1.7009 15.5082
Evsa-T GDSC1; GDSC2 1.9867 3.4505 1.8277 14.1947
UACC-893 GDSC2 2.0519 3.9669 1.7187 14.5242
ZR-75-30 GDSC2; CTRP2; CCLE 2.3276 4.17 2.3079 24.8279
BT-474 GDSC1; GDSC2; CTRP2; CCLE 2.3869 4.4757 2.3472 24.5002
Hs 578T GDSC2; CTRP2; CCLE 2.4282 4.7072 2.3666 24.2998
MDA-MB-468 GDSC2; CTRP2; CCLE 2.4684 4.3737 2.4407 23.9168
HCC1500 GDSC1; GDSC2; CTRP2 2.5001 4.3345 2.4765 23.6921
MDA-MB-453 GDSC2; CTRP2; CCLE 2.529 4.1379 2.517 23.4604
MFM-223 GDSC1; GDSC2 2.5354 4.6183 1.9408 11.2962
HCC1187 GDSC1; GDSC2; CCLE 2.7737 4.4477 2.2556 7.1079
CAL-120 GDSC2 2.7792 4.3648 2.3 8.2138
HCC1599 GDSC1; GDSC2 3.1087 4.7267 2.4348 6.247
MDA-MB-361 GDSC2; CTRP2 3.1347 4.3149 3.13 19.4006
HCC1569 GDSC2; CCLE 3.1739 6.1308 1.7923 8.4293
MDA-MB-175-VII GDSC2; CCLE 3.1871 4.6031 2.5658 4.3259
MDA-MB-415 GDSC2; CCLE 3.2089 5.9377 1.9187 7.6763
EFM-19 GDSC2; CCLE 3.215 6.2343 1.7757 8.4138
MDA-MB-157 GDSC2; CTRP2; CCLE 3.2312 4.955 3.1889 18.8849
HCC70 GDSC2; CCLE 3.4511 5.2999 2.4384 4.3551
HCC1428 GDSC2; CTRP2 3.453 7.1682 2.8459 19.46
EFM-192A GDSC2 3.4604 7.3397 1.4272 11.5028
SK-BR-3 CTRP2; CCLE 3.4648 5.5354 3.3501 17.5792
COLO 824 GDSC1; GDSC2 3.4757 6.3861 1.916 8.4285
MDA-MB-330 GDSC2 3.4871 7.886 1.176 12.944
YMB-1-E GDSC2 3.4993 6.3785 1.9388 8.2494
MDA-MB-436 GDSC2; CCLE 3.6296 5.9944 2.2327 5.0403
BT-20 GDSC2; CTRP2; CCLE 3.6424 5.8943 3.4624 16.6284
AU565 GDSC2; CTRP2; CCLE 3.7022 6.0648 3.4827 16.3723
UACC-812 GDSC1; GDSC2; CTRP2; CCLE 3.742 7.5788 2.9936 18.089
CAL-85-1 GDSC2; CTRP2; CCLE 3.899 5.7831 3.7689 14.7425
BT-483 GDSC2 3.9116 8.3 1.3056 11.0129
MDA-MB-231 GDSC2; CTRP2 3.99 6.3789 3.7028 14.7062
T-47D GDSC2; CTRP2; CCLE 4.0911 7.8444 3.2487 16.1562
Hs 578Bst CTRP2 4.3799 5.607 4.3259 11.2732
HCC38 GDSC2; CTRP2 4.5845 6.356 4.3564 10.5396
HCC1937 GDSC2; CTRP2 4.6313 6.8122 4.2411 10.8409
HCC1419 GDSC2; CTRP2 4.6764 8.5025 3.5481 13.4661
KPL-1 CTRP2 4.7598 7.2129 4.2123 10.6032
CAL-51 GDSC2; CTRP2 5.0988 8.2834 4.0644 10.3472
HDQ-P1 GDSC2; CTRP2; CCLE 5.123 6.2833 4.9648 6.7047
Hs 739.T CCLE 5.6009 8.7943 1.876 1.9275
HCC202 CTRP2 5.7064 11.1035 3.2279 12.466
HCC1395 GDSC2; CTRP2; CCLE 6.5902 11.3109 3.8511 8.208
MCF-7 GDSC2; CTRP2; CCLE 6.857 11.5042 3.9585 7.3107
HMC-1-8 CTRP2; CCLE 7.2314 11.5557 4.2043 5.7182
BT-549 GDSC2; CTRP2; CCLE 7.3975 12.518 3.8541 6.8859
ZR-75-1 CTRP2; CCLE 7.4209 8.9262 5.5251 0.5744
HCC1954 GDSC2; CTRP2; CCLE 7.4779 11.4642 4.4159 4.5209
HCC1143 GDSC2; CTRP2 7.7235 10.731 4.9084 2.345
CAL-148 GDSC1; GDSC2; CTRP2 7.8184 9.0915 5.6294 0.1765
CAMA-1 GDSC2; CTRP2; CCLE 7.8858 18.0354 1.5058 15.0132
HCC1806 GDSC2; CTRP2; CCLE 8.0399 9.5962 5.5326 0.2739
JIMT-1 GDSC2; CTRP2 8.0671 10.1364 5.3382 0.6928
BT 231 CTRP2 2.4771 5.1899 2.3469 24.2102
BT 239 CTRP2 2.5297 2.9725 2.5297 23.4152
BT 172 CTRP2 2.7001 4.2922 2.6859 22.3278
BT 271 CTRP2 2.7841 5.1642 2.6822 22.068
BT 145 CTRP2 2.8583 5.3081 2.7372 21.6404
BT 139 CTRP2 2.9108 4.4786 2.8933 20.9353
BT164 CTRP2 2.9287 5.0485 2.8552 21.0069
BT 504 CTRP2 3.1135 4.7771 3.0826 19.63
BT 245 CTRP2 3.1189 5.5152 2.979 19.9708
BT 428 CTRP2 3.1671 5.0338 3.1115 19.3574
BT 228 CTRP2 3.2439 4.6005 3.2308 18.701
BT 248 CTRP2 3.3313 6.4228 2.9721 19.346
BT 286 CTRP2 3.4145 6.0199 3.1809 18.337
BT 131 CTRP2 3.4215 5.8007 3.2446 18.0873
BT 440 CTRP2 3.4926 5.3272 3.4175 17.2562
BT 112 CTRP2 3.5436 6.8871 3.0462 18.4497
BT 330 CTRP2 3.5708 5.3453 3.4987 16.725
BT147 CTRP2 3.6915 5.6656 3.5693 16.0963
BT 482 CTRP2 4.0886 5.6107 4.0108 13.2963
BT 333 CTRP2 4.1331 6.3452 3.8693 13.6694
BT 159 CTRP2 4.1943 5.1181 4.1841 12.36
BT 444 CTRP2 4.2027 6.6034 3.8582 13.5073
BT 416 CTRP2 4.2037 5.3549 4.1734 12.3654
BT 187 CTRP2 4.2222 5.8296 4.1101 12.5274
BT 179 CTRP2 4.2892 5.9991 4.1411 12.2102
BT 422 CTRP2 4.5297 6.3165 4.3098 10.8728
BT 359 CTRP2 4.5798 6.5474 4.2851 10.8196
BT 216 CTRP2 4.632 6.7909 4.2501 10.8045
BT 340 CTRP2 4.75 6.9002 4.332 10.1631
BT 224 CTRP2 5.2162 9.5769 3.548 12.1991
BT 328 CTRP2 5.237 6.8594 4.8582 6.8008
BT 232 CTRP2 5.3214 6.6238 5.0463 5.8387
BT 320 CTRP2 5.533 7.6216 4.7976 6.3191
BT 498 CTRP2 5.6766 6.1681 5.6036 2.7132
⏷ Show the Full List of 92 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 7.9738 14.2208 3.4309 7.7234
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Onda 10 GDSC1; GDSC2 0.952 2.5659 0.8959 24.0691
D-423MG GDSC2 1.3447 3.5437 1.0998 21.142
KNS-42 GDSC1; GDSC2; CTRP2; CCLE 2.0365 4.8455 1.9298 27.0626
D283 Med GDSC1; GDSC2; CTRP2 2.2306 3.8912 2.221 25.4401
D-336MG GDSC1; GDSC2 2.299 4.7103 1.6616 13.9181
TM-31 CTRP2 2.3065 2.8181 2.3065 24.9021
PFSK-1 GDSC2 2.541 7.0645 0.7657 18.3705
D-566MG GDSC2 2.5479 4.1855 2.149 10.0337
AM-38 GDSC1; GDSC2 2.5493 3.3849 2.4607 8.2236
GB-1 GDSC1; GDSC2; CTRP2; CCLE 2.5618 3.9904 2.5557 23.222
SF539 GDSC1; GDSC2; CTRP2 2.7233 3.8434 2.7218 22.1307
8-MG-BA GDSC1; GDSC2; CTRP2; CCLE 2.8168 3.8342 2.8159 21.5056
SF268 GDSC1; GDSC2; CTRP2 2.8612 4.2006 2.8546 21.229
SF126 GDSC1; GDSC2; CTRP2; CCLE 2.9346 4.3956 2.9224 20.7588
Daoy GDSC2; CTRP2; CCLE 2.9889 4.0707 2.9869 20.3626
42-MG-BA GDSC2; CTRP2; CCLE 3.1281 7.552 2.3525 22.2266
Becker GDSC1; GDSC2; CTRP2 3.1288 4.4567 3.1191 19.4566
D-502MG GDSC1; GDSC2 3.1522 4.704 2.4848 5.8149
MOG-G-UVW GDSC2 3.185 4.7311 2.5002 5.6152
T98G GDSC2; CTRP2; CCLE 3.2188 5.8578 3.0096 19.5515
GaMG GDSC2; CTRP2; CCLE 3.2769 4.7598 3.2549 18.5112
D-263MG GDSC1; GDSC2 3.2801 4.5352 2.6801 4.1869
D-245MG GDSC2 3.2867 7.1787 1.3641 12.4332
KNS-81-FD GDSC1; GDSC2 3.2912 4.7809 2.5667 4.872
H4 GDSC2; CCLE 3.3347 4.7658 2.6106 3.7197
KNS-60 CTRP2; CCLE 3.3568 4.5601 3.3488 17.932
GI-1 GDSC1; GDSC2; CCLE 3.3889 4.9864 2.5448 3.9383
M059J GDSC2; CCLE 3.4249 4.8879 2.623 3.4431
Onda 11 GDSC1; GDSC2 3.4797 7.2875 1.4691 11.2301
D-542MG GDSC1; GDSC2 3.4912 10.0396 0.1031 18.9119
ONS-76 GDSC1; GDSC2; CTRP2; CCLE 3.6232 5.5828 3.5123 16.5114
SK-MG-1 GDSC2 3.6636 5.129 2.6849 3.1421
SF295 GDSC2; CTRP2; CCLE 3.6777 6.3081 3.385 16.8012
A-172 GDSC2; CTRP2; CCLE 3.6951 6.4121 3.3715 16.7992
LN-229 GDSC2; CTRP2; CCLE 3.7245 5.8418 3.5649 16.0091
LN-405 GDSC2 3.7411 5.8168 2.4042 4.6994
D-247MG GDSC1; GDSC2 3.838 8.7355 1.0323 12.8619
D-392MG GDSC1; GDSC2 3.8773 14.0283 -1.5758 24.9056
DBTRG-05MG GDSC2; CTRP2; CCLE 3.9297 6.4712 3.6073 15.2369
SNU-738 CTRP2 3.9982 5.3349 3.9575 13.7699
MOG-G-CCM GDSC2; CCLE 4.055 6.104 2.4842 2.9258
CAS-1 GDSC1; GDSC2; CTRP2; CCLE 4.1354 5.2548 4.1119 12.7972
KNS-81 CTRP2; CCLE 4.1509 5.8163 4.0355 13.0138
KG-1-C CTRP2 4.2809 5.9365 4.1482 12.21
Hs 683 GDSC2; CTRP2; CCLE 4.3176 5.9367 4.1882 11.954
U-251MG GDSC2; CTRP2 4.3696 5.6022 4.3156 11.3418
U-118MG GDSC2; CTRP2; CCLE 4.4756 6.5469 4.1729 11.5404
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 4.567 7.9301 1.9545 5.6264
SW1088 GDSC2; CTRP2; CCLE 4.5754 6.5231 4.289 10.8175
GOS-3 CTRP2 4.627 6.8452 4.2236 10.9197
SNU-626 CTRP2 4.6865 6.3001 4.4855 9.7617
M059K CTRP2 4.7926 7.8689 3.9558 11.537
SW1783 GDSC2; CTRP2 4.8108 7.0342 4.3409 9.964
KALS-1 GDSC1; GDSC2; CTRP2; CCLE 4.8621 6.8425 4.4737 9.3089
SNB-75 GDSC1; GDSC2; CTRP2 4.888 6.4449 4.6541 8.5471
YKG-1 GDSC2; CTRP2; CCLE 5.0152 6.3979 4.8081 7.603
YH-13 GDSC2; CTRP2 5.0876 7.7954 4.2836 9.4816
GMS-10 CTRP2; CCLE 5.1509 7.886 4.3033 9.2476
DK-MG GDSC2; CTRP2; CCLE 5.1625 7.8002 4.3551 9.0089
SNU-489 CTRP2 5.2772 6.5084 5.0468 5.957
NMC-G1 GDSC1; GDSC2; CTRP2 5.294 7.0746 4.8211 6.8012
CCF-STTG1 CTRP2 5.4043 11.1802 2.9253 14.327
KINGS-1 GDSC1; GDSC2 5.5135 7.8731 2.51 1.3164
1321N1 CCLE 5.595 8.9371 1.8135 2.1785
SNU-466 CTRP2 6.7575 9.7148 4.7642 4.1506
U-87MG ATCC GDSC1; GDSC2; CTRP2; CCLE 7.0991 9.9453 4.8873 3.1647
LN-18 GDSC2; CTRP2; CCLE 7.4084 9.9635 5.0711 2.0886
SNU-201 CTRP2 7.4884 12.1293 4.105 5.7444
SNU-1105 CTRP2 8.1775 14.1801 3.5874 6.8291
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 2.398 5.1245 1.5693 14.1027
ETK-1 GDSC1; GDSC2 2.9434 4.6844 2.3043 7.6352
TGBC1TKB GDSC1; GDSC2 3.4737 5.9667 2.1238 7.1548
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-265 CTRP2; CCLE -0.7551 2.3204 -0.7766 45.3447
HEC-50B CTRP2 0.9861 14.3288 -3.2989 39.2103
AN3-CA GDSC2; CTRP2; CCLE 2.3434 5.0062 2.2342 25.0279
JHUEM-1 CTRP2 2.4003 2.9373 2.4003 24.2772
HEC-1-B CCLE 2.5994 3.5982 2.325 4.7937
HEC-151 CTRP2; CCLE 2.8176 3.421 2.8176 21.4976
MFE-319 GDSC2; CTRP2; CCLE 3.0641 4.4148 3.0545 19.8873
HEC-1-A CTRP2; CCLE 3.1769 4.8463 3.1428 19.2184
MFE-280 GDSC2; CCLE 3.2203 4.5819 2.6054 4.0316
MFE-296 GDSC2; CTRP2; CCLE 3.3867 5.4358 3.2846 18.0555
JHUEM-7 CTRP2 3.6226 5.4747 3.5324 16.4429
EN GDSC2; CTRP2; CCLE 3.6333 5.9575 3.4364 16.7494
KLE GDSC2; CTRP2; CCLE 3.9999 5.7788 3.8797 14.0356
EFE-184 CTRP2; CCLE 4.4494 6.1739 4.2667 11.2698
JHUEM-3 CTRP2 4.6372 6.8235 4.2429 10.8178
ESS-1 GDSC2; CTRP2; CCLE 4.9726 7.2911 4.3977 9.3132
RL95-2 GDSC1; GDSC2; CTRP2; CCLE 5.2337 7.4992 4.5659 7.9797
TEN CCLE 6.0702 7.6235 2.5054 0.0784
HEC-6 CTRP2; CCLE 7.0722 9.4066 5.1231 2.2801
HEC-108 CTRP2 7.6671 9.22 5.5198 0.4516
JHUEM-2 CTRP2; CCLE 7.8634 10.4919 5.0911 1.5756
HEC-251 CTRP2; CCLE 7.8894 9.6581 5.4467 0.5163
HEC-59 CTRP2; CCLE 8.128 10.567 5.1931 1.0531
Ishikawa (Heraklio) 02 ER- CTRP2; CCLE 7.5187 8.9985 5.5408 0.4765
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BB65-RCC GDSC1; GDSC2 0.5263 3.8616 0.1082 30.1618
LB2241-RCC GDSC1; GDSC2 1.6874 3.8617 1.3662 18.1424
UO-31 GDSC2; CTRP2 1.985 3.2162 1.9842 27.0467
A-704 GDSC2 2.0912 5.1023 1.2746 17.0261
SW13 GDSC2 2.1586 3.4025 2.0295 12.3587
ACHN GDSC2; CTRP2; CCLE 2.1911 3.2417 2.1908 25.6724
LB996-RCC GDSC1; GDSC2 2.633 4.2887 2.1894 9.4624
SW156 GDSC2 2.7842 5.6374 1.6904 11.9984
KTCTL-140 GDSC2 2.8356 4.3165 2.3779 7.5597
786-O GDSC2; CTRP2; CCLE 2.9129 4.394 2.9 20.9057
HA7-RCC GDSC1; GDSC2 2.9195 4.1098 2.5573 6.1543
NCC021 GDSC2 2.9433 5.0815 2.1096 8.8523
KTCTL-195 GDSC2 3.0498 4.2044 2.6375 5.1951
KTCTL-13 GDSC2 3.079 4.4617 2.5388 5.7129
KTCTL-26A GDSC2 3.1191 4.4918 2.5603 5.4461
LB1047-RCC GDSC1; GDSC2 3.1554 4.8681 2.4061 6.3016
CAL-54 GDSC2; CTRP2 3.237 5.1348 3.1725 18.9224
NCC010 GDSC2 3.4016 5.472 2.3126 6.1625
KTCTL-21 GDSC2 3.4367 8.1354 1.0101 14.1151
SNU-1272 CTRP2 3.5231 5.3816 3.4413 17.0764
VMRC-RCW GDSC2; CTRP2; CCLE 3.5586 6.1103 3.3133 17.4209
KTCTL-1M GDSC2 3.6238 7.6567 1.4007 11.2458
TUHR10TKB CTRP2 3.6774 5.3271 3.6158 15.9788
A-498 GDSC1; GDSC2; CTRP2 3.7172 7.1362 3.1409 17.5976
BFTC-909 GDSC2; CTRP2 3.9551 5.4853 3.889 14.1446
SN12C GDSC2 4.0053 5.9308 2.5336 3.3189
KMRC-3 CTRP2 4.0241 5.6112 3.941 13.7442
RXF 393L GDSC1; GDSC2 4.0469 6.3766 2.3484 4.3475
VMRC-RCZ GDSC2; CTRP2; CCLE 4.0951 5.9727 3.9362 13.5405
TK-10 GDSC1; GDSC2 4.1794 6.365 2.4419 3.5161
Caki-1 GDSC2; CTRP2 4.4401 6.2894 4.2211 11.465
Caki-2 CTRP2; CCLE 4.6032 7.1855 4.0606 11.6157
KMRC-1 GDSC2; CTRP2; CCLE 4.7118 7.3939 4.0849 11.2314
TUHR14TKB CTRP2 4.7795 6.9552 4.3407 10.0492
RCC10RGB GDSC1; GDSC2; CTRP2 4.8079 6.1497 4.6648 8.7422
TUHR4TKB CTRP2 4.9455 6.4141 4.7272 8.1072
KMRC-2 CTRP2; CCLE 5.3416 8.0613 4.4036 8.3851
OS-RC-2 GDSC1; GDSC2; CTRP2 6.6029 10.0744 4.4738 5.5988
769-P GDSC2; CTRP2; CCLE 8.5774 10.1907 5.5239 0.1529
KMRC-20 GDSC2; CTRP2 8.6223 10.271 5.5123 0.1585
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H716 GDSC1; GDSC2; CTRP2 1.5252 4.9222 1.3673 30.6351
COLO 320HSR GDSC1; GDSC2 1.6766 3.2888 1.5352 17.2543
HCC2998 GDSC1; GDSC2 2.5251 3.8937 2.2495 9.5312
GP5d GDSC2 2.5538 3.7652 2.3315 8.9351
KM12 GDSC1; GDSC2; CTRP2 2.6249 5.345 2.4776 23.2857
COLO 320 CTRP2; CCLE 2.6569 4.2935 2.6413 22.6202
SNU-407 GDSC2; CTRP2 2.671 3.6336 2.6706 22.4756
HCT 15 GDSC2; CTRP2; CCLE 2.6716 3.3419 2.6716 22.4703
SNU-C5 GDSC2; CTRP2 2.6873 4.1559 2.6785 22.395
SW1463 GDSC2 2.8005 4.653 2.184 8.8788
RKO GDSC1; GDSC2; CTRP2; CCLE 2.897 4.2661 2.8891 20.9946
SW480 CCLE 2.9746 4.466 2.2457 4.1509
SW620 GDSC2; CTRP2; CCLE 2.9756 4.2179 2.9706 20.4615
SNU-C1 GDSC1; GDSC2; CTRP2 3.1675 5.4106 3.0523 19.5608
NCI-H747 GDSC1; GDSC2; CTRP2; CCLE 3.1964 4.8714 3.1609 19.0935
LS513 GDSC1; CTRP2; CCLE 3.2675 4.67 3.2512 18.5548
SW626 GDSC2 3.3087 5.5801 2.1818 7.2567
SNU-61 GDSC2; CTRP2 3.3234 5.5579 3.1922 18.5789
DiFi GDSC2 3.3315 6.4842 1.7488 9.9189
GP2d CTRP2 3.3519 5.6404 3.2057 18.4419
CaR-1 GDSC2 3.4146 4.9345 2.5915 4.3624
SNU-81 GDSC2 3.422 6.4438 1.8436 9.064
HT-55 GDSC2; CTRP2 3.4554 5.9267 3.2501 17.9631
LS123 GDSC1; GDSC2; CTRP2; CCLE 3.4884 4.8628 3.4677 17.0978
SNU-1033 CTRP2 3.5098 4.9008 3.4871 16.962
SNU-C2B GDSC2; CCLE 3.5351 5.097 2.6052 3.2932
SNU-283 GDSC2 3.5493 5.337 2.497 4.598
C2BBe1 GDSC1; GDSC2; CTRP2; CCLE 3.5528 5.3376 3.4805 16.8456
T84 GDSC2; CTRP2; CCLE 3.5552 5.3443 3.482 16.8327
SW1116 GDSC2 3.5679 5.2249 2.5669 4.1113
SW837 GDSC2 3.6335 5.3163 2.571 3.9219
SNU-175 GDSC2; CTRP2 3.7006 6.4048 3.3798 16.7523
SW948 GDSC2; CTRP2 3.7119 5.7118 3.5814 15.9897
SK-CO-1 GDSC2; CTRP2; CCLE 3.74 5.1846 3.7016 15.4821
CL-11 GDSC1; GDSC2; CTRP2 3.7488 6.2977 3.4657 16.2939
LS411N GDSC1; GDSC2; CTRP2; CCLE 3.8053 4.9799 3.7893 14.9708
HCT 116 GDSC2; CTRP2; CCLE 3.8139 9.5192 2.2204 20.8441
DLD-1 CTRP2 3.8526 5.3675 3.7975 14.7892
COLO 678 GDSC2; CTRP2; CCLE 3.9084 6.113 3.6942 14.982
SW48 GDSC2; CTRP2; CCLE 3.9977 5.1112 3.9802 13.694
SW1417 GDSC2; CTRP2; CCLE 4.0579 6.5814 3.7092 14.4836
HCT 8 CTRP2 4.0857 5.648 4.0005 13.3416
SNU-C4 CTRP2 4.1251 5.6371 4.0453 13.0599
LS1034 GDSC1; GDSC2; CTRP2 4.2253 6.2126 4.0108 12.8762
NCI-H508 GDSC2; CTRP2 4.4907 6.9657 4.0314 12.0359
COLO205 GDSC2; CTRP2; CCLE 4.5498 7.2895 3.9613 12.1467
RCM-1 [Human ESC] GDSC2; CTRP2 4.9144 7.5217 4.2357 10.1077
HCC-56 CTRP2; CCLE 5.174 6.8347 4.8037 7.1819
HT115 GDSC2; CTRP2 5.2641 8.3785 4.1769 9.4979
SNU-503 CTRP2 5.5445 6.9564 5.1257 4.9488
SW403 CCLE 6.3715 8.2604 2.3956 0.1448
HT-29 GDSC2; CTRP2; CCLE 7.4391 9.3769 5.3467 1.0991
CW-2 GDSC1; GDSC2; CTRP2 7.6041 11.7292 4.373 4.5217
MDST8 GDSC1; GDSC2; CTRP2 7.8881 8.9625 5.6999 0.0742
OUMS-23 CTRP2 7.9393 9.1175 5.6649 0.1028
COLO201 CTRP2; CCLE 8.0006 9.0609 5.7058 0.0553
LS180 GDSC2; CTRP2 8.2254 10.0287 5.4472 0.3706
LoVo GDSC2; CTRP2 8.4152 10.3793 5.3938 0.4057
SNU-C2A CTRP2; CCLE 8.581 12.3617 4.6652 2.3631
CCK-81 GDSC2; CTRP2; CCLE 8.694 10.3064 5.5259 0.1304
⏷ Show the Full List of 60 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 2.8567 3.7967 2.6363 5.9156
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Huh-7 GDSC2 1.6607 4.08 1.2573 18.8731
SNU-886 CTRP2 1.9037 4.6627 1.8141 27.8882
HuH-6 CTRP2 2.2972 4.0063 2.2847 25.0063
PLC/PRF/5 CTRP2; CCLE 2.3891 4.3823 2.3574 24.4583
Li-7 CTRP2 2.4602 5.1271 2.3397 24.2891
JHH-7 GDSC2; CCLE 2.7373 4.0598 2.398 6.5011
SK-HEP-1 GDSC2; CTRP2; CCLE 2.7794 3.7364 2.7789 21.7537
JHH-5 CTRP2; CCLE 2.909 5.2611 2.8003 21.2596
HLF CTRP2; CCLE 2.9122 5.5351 2.7506 21.4233
SNU-182 CTRP2; CCLE 2.9177 4.989 2.8517 21.0543
JHH-1 GDSC2; CTRP2 3.0102 4.7741 2.9744 20.335
Hep-G2/C3A GDSC2; CCLE 3.1462 4.2926 2.6834 3.8179
JHH-2 GDSC2; CTRP2; CCLE 3.1692 4.2664 3.166 19.1657
SNU-878 CTRP2 3.2321 4.6111 3.218 18.7832
JHH-4 GDSC2; CTRP2; CCLE 3.3067 5.0995 3.2517 18.4253
HuH-1 GDSC2; CTRP2; CCLE 3.3845 6.019 3.1484 18.5454
HLE GDSC2; CCLE 3.4546 5.4527 2.365 4.7333
SNU-398 GDSC2; CTRP2; CCLE 3.8737 6.3358 3.5899 15.4665
SNU-449 GDSC2; CTRP2; CCLE 3.9797 6.5953 3.6198 15.0444
SNU-423 GDSC2; CTRP2; CCLE 4.2148 6.1684 4.0125 12.9013
SNU-387 GDSC2; CTRP2; CCLE 4.606 7.0364 4.1249 11.3582
JHH-6 GDSC2; CTRP2; CCLE 5.5086 6.0892 5.4469 3.787
SNU-475 CTRP2; CCLE 7.0749 22.7308 -1.4564 24.8438
Hep-G2 CTRP2; CCLE 8.054 9.2991 5.6435 0.1073
Hep 3B2.1-7 GDSC2; CTRP2; CCLE 8.0624 19.7892 0.7727 17.1217
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 227 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LC-1F CTRP2 -0.3108 18.1478 -5.872 46.793
NCI-H1703 GDSC2; CTRP2; CCLE 0.3787 5.8084 -0.076 38.9589
NCI-H2171 GDSC1; GDSC2 1.4423 5.1918 0.5725 23.6274
NCI-H1963 GDSC1; GDSC2 1.4748 2.8792 1.4074 18.883
DMS 454 CTRP2 1.4868 4.8762 1.3339 30.8734
NCI-H1581 GDSC1; GDSC2; CTRP2; CCLE 1.5786 3.7927 1.5549 29.831
A-427 GDSC2 1.7462 4.4887 1.1864 18.9185
NCI-H510A GDSC1; GDSC2 1.8221 4.1926 1.3861 17.4537
NCI-H835 GDSC2 1.8569 4.4148 1.3331 17.6155
NCI-H1385 CTRP2 1.8938 3.1856 1.8928 27.6554
DMS 53 GDSC2; CTRP2 1.9011 4.3608 1.8471 27.7849
NCI-H847 GDSC1; GDSC2 1.9148 2.7039 1.9008 14.1917
Lu-139 GDSC1 1.948 3.5256 1.1934 6.5519
COLO 677 CCLE 1.9773 3.3652 1.7665 9.7636
NCI-H720 GDSC1; GDSC2 2.0564 3.1963 1.973 13.1353
NCI-H1648 GDSC1; GDSC2; CCLE 2.0639 3.4649 1.9074 11.2074
NCI-H1341 GDSC2; CTRP2; CCLE 2.0678 3.6761 2.0615 26.5136
Calu-6 GDSC1; GDSC2; CTRP2; CCLE 2.0691 3.9218 2.0541 26.5339
NCI-H146 GDSC2; CTRP2 2.1504 3.7462 2.1436 25.9652
NCI-H209 GDSC1; GDSC2 2.1572 3.5398 1.9853 12.6096
UMC-11 GDSC2 2.2188 4.1041 1.8411 13.1717
NCI-H1573 GDSC2; CTRP2; CCLE 2.2561 3.9952 2.243 25.2819
NCI-H2795 GDSC2 2.2803 3.5328 2.1213 11.3058
COR-L279 GDSC2 2.3027 4.4238 1.7928 13.1194
SHP-77 GDSC1; GDSC2; CTRP2; CCLE 2.3066 4.4845 2.2619 25.0523
NCI-H841 GDSC2; CTRP2 2.3502 4.7608 2.277 24.8591
NCI-H82 GDSC1; GDSC2 2.3849 3.4015 2.2766 9.9781
NCI-H1437 GDSC2 2.3985 7.5935 0.375 21.016
NCI-H2081 GDSC1; GDSC2; CTRP2 2.4004 5.5326 2.1947 24.9834
NCI-H1770 GDSC1; GDSC2 2.403 12.9253 -2.2655 31.3743
DMS 273 GDSC2; CTRP2 2.4053 4.4115 2.372 24.3563
NCI-H810 GDSC2; CTRP2; CCLE 2.4204 3.4689 2.4199 24.145
NCI-H2087 GDSC2; CTRP2; CCLE 2.4253 4.8139 2.3501 24.3656
IST-SL2 GDSC1; GDSC2 2.4483 4.8988 1.7244 12.9753
Ms-1 GDSC1; GDSC2 2.4574 3.4448 2.3422 9.2905
IST-SL1 GDSC1; GDSC2 2.471 4.3801 1.9842 11.3191
NCI-H64 GDSC1; GDSC2 2.4888 4.4651 1.9641 11.3716
NCI-H2369 GDSC2 2.4911 3.4799 2.3677 8.9991
NCI-H524 GDSC1; GDSC2 2.494 6.9833 0.7626 18.5511
NCI-H1876 GDSC1; GDSC2 2.4961 3.9707 2.1873 10.0132
NCI-H211 GDSC1; GDSC2; CTRP2; CCLE 2.4998 3.9028 2.4949 23.631
NCI-H1944 GDSC2; CTRP2; CCLE 2.5344 3.7882 2.5319 23.3925
NCI-H2135 GDSC1; GDSC2 2.5416 4.1957 2.138 10.1244
LB647-SCLC GDSC1; GDSC2 2.5655 4.6607 1.9511 11.1613
NCI-H250 GDSC2 2.5836 5.2089 1.7096 12.5741
HCC44 GDSC2; CTRP2; CCLE 2.5952 4.1151 2.5859 23.0101
NCI-H2029 GDSC2; CTRP2 2.6003 4.0011 2.5946 22.9642
NCI-H1755 GDSC2; CTRP2 2.6397 3.8156 2.6379 22.6885
NCI-H23 GDSC1; GDSC2; CTRP2; CCLE 2.6552 4.7423 2.603 22.7555
SBC-5 GDSC2; CTRP2; CCLE 2.6594 3.8906 2.6567 22.5604
Lu-99 CTRP2; CCLE 2.6603 3.2425 2.6603 22.5453
COR-L23 GDSC2; CCLE 2.6806 3.5303 2.5558 5.9228
NCI-H1436 GDSC1; GDSC2 2.6918 8.7433 0.0697 21.5828
NCI-H2803 GDSC2 2.7138 4.2309 2.2969 8.5056
RERF-LC-MS GDSC2; CTRP2; CCLE 2.7172 3.7919 2.7161 22.1701
NCI-H1155 GDSC1; GDSC2; CTRP2; CCLE 2.7223 4.2669 2.71 22.1733
COR-L303 GDSC2 2.7261 3.5304 2.6048 6.638
NCI-H446 GDSC1; GDSC2; CTRP2 2.7322 4.371 2.7148 22.1245
COR-L321 GDSC2 2.7329 4.4648 2.2076 8.9774
NCI-H1304 GDSC1 2.7431 4.4821 1.31 3.2653
Lu-65 GDSC1; GDSC2; CTRP2 2.7679 4.8126 2.7144 22.0094
NCI-H2106 CTRP2 2.7786 4.9197 2.7127 21.9804
Lu-135 GDSC2 2.7866 4.0801 2.4388 7.3713
VMRC-LCD GDSC2; CTRP2; CCLE 2.7952 4.3347 2.7818 21.6914
NCI-H2227 GDSC1; GDSC2 2.8083 4.2317 2.3908 7.5812
NCI-H2731 GDSC2 2.8279 4.0575 2.4906 6.9012
SBC-1 GDSC1; GDSC2 2.833 4.057 2.4959 6.8496
RERF-LC-Sq1 GDSC2 2.8338 5.3297 1.887 10.6086
NCI-H1568 GDSC2; CTRP2; CCLE 2.8443 4.0579 2.841 21.3304
Lu-99A GDSC2 2.8452 4.4092 2.3434 7.7364
Sq-1 CTRP2; CCLE 2.8532 4.06 2.8499 21.2711
LK2 CTRP2 2.8773 4.3825 2.864 21.1442
HOP-62 GDSC1; GDSC2; CTRP2 2.8871 3.9322 2.8859 21.0385
NCI-H2342 GDSC2; CTRP2 2.8941 6.7828 2.3797 22.811
NCI-H1688 GDSC2 2.8941 4.588 2.3046 7.8034
NCI-H2810 GDSC2 2.8984 5.0533 2.0821 9.1738
NCI-H1105 GDSC2; CTRP2 2.8988 4.9366 2.8384 21.161
NCI-H1694 GDSC1; GDSC2; CTRP2; CCLE 2.9291 4.053 2.9268 20.762
CPC-N GDSC1; GDSC2 2.9326 3.7682 2.7267 5.078
COLO 668 GDSC1; GDSC2; CTRP2 2.9413 4.77 2.9023 20.8047
NCI-H2804 GDSC2 2.9506 4.6469 2.3292 7.4552
LC-1/sq GDSC2 2.9511 5.2921 2.013 9.4312
IA-LM GDSC2; CTRP2; CCLE 2.9735 4.5932 2.9509 20.5347
NCI-H1092 GDSC1; GDSC2; CTRP2; CCLE 2.992 4.2997 2.985 20.3591
SBC-3 GDSC2 3.027 4.4227 2.5099 6.0685
NCI-H740 GDSC2 3.0334 6.134 1.6687 11.3225
COR-L311 GDSC2 3.0499 5.652 1.9231 9.6777
NCI-H1395 CTRP2 3.0711 5.1816 2.9879 20.0918
NCI-H1563 GDSC2; CTRP2; CCLE 3.0771 4.012 3.0763 19.7715
NCI-H1048 GDSC2; CCLE 3.0924 4.321 2.6202 4.2958
Lu-165 GDSC1; GDSC2 3.0991 4.5726 2.5024 5.875
HCC1438 CTRP2 3.1015 4.2584 3.0976 19.6191
HARA [Human squamous cell lung carcinoma] GDSC2; CTRP2; CCLE 3.1183 4.5227 3.1053 19.5378
HCC1833 CTRP2 3.1242 7.3946 2.4086 22.0309
NCI-H2461 GDSC2 3.1281 4.9769 2.3278 6.8815
NCI-H69 GDSC1; GDSC2; CTRP2 3.1458 4.8027 3.1142 19.4173
NCI-H187 GDSC1 3.1474 11.727 -1.9435 22.708
NCI-H1975 GDSC1; GDSC2; CTRP2; CCLE 3.15 4.4207 3.1423 19.3087
COR-L32 GDSC2 3.1593 4.4669 2.6088 5.0114
DV-90 CTRP2; CCLE 3.1599 4.7366 3.1346 19.302
NCI-H322M GDSC1; GDSC2 3.1853 4.4894 2.6208 4.8531
EKVX GDSC1; GDSC2; CTRP2 3.1979 5.6028 3.0464 19.4856
HCC33 GDSC1; GDSC2 3.2173 4.6523 2.5676 5.089
EMC-BAC-2 GDSC2 3.2259 4.5224 2.6399 4.6058
RERF-LC-KJ GDSC2 3.2437 4.3972 2.7178 4.0588
NCI-H2228 GDSC2; CTRP2; CCLE 3.2762 4.8171 3.2496 18.5314
NCI-H2170 GDSC2; CTRP2; CCLE 3.28 4.9088 3.2452 18.5339
NCI-H2869 GDSC2 3.2986 5.385 2.2709 6.7223
NCI-H1693 GDSC2; CTRP2; CCLE 3.3054 4.3596 3.3023 18.2579
NCI-H2196 GDSC1; GDSC2; CTRP2 3.3177 5.3929 3.2179 18.5069
NCI-H345 GDSC1; GDSC2 3.3283 4.5097 2.7334 3.7081
NCI-H647 GDSC2; CTRP2; CCLE 3.3407 5.3124 3.2565 18.2994
KNS-62 GDSC2; CTRP2; CCLE 3.3453 3.9003 3.3453 17.9818
NCI-H1993 GDSC2 3.3505 5.1662 2.4235 5.6061
NCI-H1915 GDSC2; CTRP2; CCLE 3.3563 4.8734 3.3287 18.0011
NCI-H1781 GDSC2 3.357 5.4239 2.3 6.3685
ChaGo-K-1 GDSC2; CTRP2 3.3686 5.7419 3.2009 18.4067
NCI-H290 GDSC2 3.3689 5.1703 2.4366 5.4699
HCC1588 CTRP2 3.3699 5.9298 3.1562 18.5621
LC-2/ad GDSC1; GDSC2 3.3997 5.6827 2.2057 6.8436
NCI-H3122 GDSC2 3.4113 5.4843 2.3142 6.125
NCI-H838 GDSC2; CTRP2 3.4272 5.3613 3.3415 17.7286
NCI-H2722 GDSC2 3.4393 5.0401 2.5586 4.5027
NCI-H1666 GDSC1; GDSC2; CTRP2; CCLE 3.4456 5.5273 3.3308 17.7075
SK-MES-1 GDSC2; CTRP2; CCLE 3.4636 5.3239 3.3869 17.4548
CAL-12T GDSC2; CTRP2; CCLE 3.4694 5.2882 3.3987 17.3953
NCI-H2444 GDSC2; CCLE 3.4806 7.1479 1.5395 9.0117
PaCa-3 GDSC2 3.4808 5.3567 2.4337 5.1782
NCI-H2141 GDSC1; GDSC2; CTRP2 3.4879 5.8731 3.2993 17.687
SW1573 GDSC2; CCLE 3.4882 5.585 2.3258 4.863
HOP-92 GDSC2; CTRP2 3.4888 5.5926 3.3645 17.453
LK-2 GDSC2 3.5026 6.067 2.0969 7.2446
NCI-H2591 GDSC2 3.5055 5.7263 2.2691 6.1504
Calu-3 GDSC2; CTRP2; CCLE 3.5281 5.4911 3.4271 17.1097
NCI-H1836 GDSC1; GDSC2 3.543 5.1779 2.5712 4.1481
NCI-H226 GDSC1; GDSC2; CTRP2; CCLE 3.5447 4.934 3.5209 16.7334
NCI-H889 CTRP2 3.5481 5.788 3.3855 17.1938
HCC4006 CTRP2; CCLE 3.55 5.6318 3.4228 17.056
NCI-H748 GDSC1; GDSC2 3.5667 6.683 1.8408 8.6794
NCI-H1651 GDSC2; CCLE 3.5868 5.2834 2.5522 3.4605
A-549 GDSC2; CTRP2; CCLE 3.6314 5.1797 3.587 16.2259
NCI-H526 GDSC1; GDSC2; CTRP2 3.6344 5.1562 3.593 16.1956
NCI-H358 GDSC2; CTRP2; CCLE 3.6772 5.1645 3.6374 15.9049
NCI-H1355 GDSC1; GDSC2; CTRP2; CCLE 3.7167 5.1363 3.6824 15.623
HCC15 GDSC2; CTRP2; CCLE 3.7278 6.5725 3.3546 16.7655
NCI-H2347 GDSC2 3.7311 6.5973 2.0115 7.1763
PC-14 GDSC2; CTRP2; CCLE 3.7331 5.5148 3.6444 15.7019
NCI-H2405 GDSC2; CTRP2 3.7356 9.2447 2.2669 20.8754
HCC1195 CTRP2 3.7369 5.2076 3.6956 15.5125
COR-L95 GDSC1; CTRP2 3.742 5.9449 3.5581 15.9795
LOU-NH91 GDSC2; CTRP2; CCLE 3.7444 5.9223 3.5665 15.942
NCI-H2373 GDSC2 3.7619 5.653 2.4996 4.0582
NCI-H661 GDSC2; CTRP2; CCLE 3.7852 6.1589 3.2617 11.0802
ABC-1 GDSC2 3.7979 6.9839 1.8709 7.8823
LCLC-97TM1 GDSC2; CTRP2 3.8087 7.3073 3.1724 17.2208
NCI-H3255 GDSC2; CCLE 3.8325 6.3457 2.2116 4.7281
RERF-LC-A1 CTRP2; CCLE 3.851 5.6313 3.7495 14.9612
NCI-H2818 GDSC2 3.8606 6.3771 2.2167 5.5777
NCI-H513 GDSC2 3.8688 6.9505 1.9408 7.2701
NCI-H522 GDSC2; CTRP2; CCLE 3.8927 5.7366 3.7725 14.7499
NCI-H596 GDSC2 3.916 6.1123 2.3855 4.408
EBC-1 GDSC2; CTRP2; CCLE 3.9177 5.7559 3.7954 14.5908
SK-LU-1 GDSC2; CTRP2; CCLE 3.9314 5.3591 3.8829 14.2418
NCI-H2030 GDSC2; CTRP2; CCLE 3.9411 6.5992 3.5767 15.3173
NCI-H292 GDSC2; CTRP2 3.9539 5.3843 3.9034 14.0988
DMS 114 GDSC1; GDSC2; CTRP2; CCLE 3.9672 6.1614 3.7445 14.6219
Calu-1 CTRP2; CCLE 3.9706 5.3165 3.9305 13.9517
HCC366 GDSC2; CTRP2 3.9789 5.7456 3.8642 14.1562
NCI-H1373 CTRP2; CCLE 4.0034 5.206 3.9777 13.6842
NCI-H520 GDSC2; CTRP2; CCLE 4.0199 7.4164 3.3526 15.9461
SW1271 GDSC2; CTRP2; CCLE 4.0414 5.79 3.9223 13.756
NCI-H2066 GDSC2 4.0673 6.1711 2.4604 3.63
HCC2279 CTRP2 4.0905 7.1709 3.5254 15.087
DMS 79 GDSC1; GDSC2; CTRP2 4.1178 6.6757 3.741 14.1913
NCI-H2122 GDSC2; CTRP2; CCLE 4.1764 5.6771 4.0931 12.7309
NCI-H1650 GDSC2; CTRP2; CCLE 4.1983 6.0906 4.0169 12.9353
NCI-H1838 GDSC1; GDSC2; CTRP2 4.2343 5.4746 4.1904 12.2082
EPLC-272H GDSC2; CTRP2 4.2381 6.1773 4.0352 12.7484
LUDLU-1 CTRP2; CCLE 4.2414 5.9873 4.092 12.5329
COR-L105 GDSC2; CTRP2; CCLE 4.3884 6.016 4.2449 11.5336
COR-L88 GDSC1; GDSC2; CTRP2 4.4336 6.5704 4.1192 11.8632
NCI-H1792 GDSC2; CTRP2; CCLE 4.4672 6.5375 4.1671 11.5863
T3M-10 CTRP2; CCLE 4.4808 5.9772 4.3559 10.8518
HCC2935 CTRP2; CCLE 4.5206 6.5492 4.2206 11.232
NCI-H2110 GDSC2; CTRP2 4.5477 7.0261 4.0676 11.7393
EMC-BAC-1 GDSC2 4.6395 9.5156 1.2426 9.6548
LC-1/sq-SF CTRP2; CCLE 4.7296 5.963 4.6309 9.1024
HCC1171 CTRP2 4.8795 8.5763 3.7126 12.3058
NCI-H2595 GDSC2 4.9817 7.1745 2.5398 1.7384
NCI-H1869 GDSC1; GDSC2; CTRP2; CCLE 5.0286 7.5574 4.3347 9.422
RERF-LC-Ad2 CTRP2 5.1083 8.5065 3.9668 10.7239
NCI-H1339 CTRP2; CCLE 5.139 7.6072 4.4219 8.7954
NCI-H196 GDSC2; CTRP2 5.1912 8.266 4.1615 9.7309
NCI-H322 CTRP2; CCLE 5.2465 8.1136 4.2876 9.0836
NCI-H727 GDSC2; CTRP2; CCLE 5.3629 9.0673 3.9332 10.2811
SW900 CCLE 5.4124 7.4618 2.319 0.5814
NCI-H650 GDSC2; CTRP2; CCLE 5.4183 8.7024 4.1633 9.2041
HCC78 GDSC2; CTRP2; CCLE 5.9378 8.5217 4.7158 5.7936
Lu-134-A GDSC1; GDSC2 6.1011 17.3484 -1.5318 19.4382
NCI-H1793 GDSC2; CTRP2; CCLE 6.3403 10.5848 4.0159 7.9677
LCLC-103H GDSC2; CTRP2; CCLE 6.3546 10.5389 4.0501 7.7989
NCI-H1299 GDSC1; GDSC2; CTRP2; CCLE 6.3881 10.8579 3.9177 8.2904
NCI-H1184 CTRP2; CCLE 6.5823 10.2544 4.3691 6.0683
RERF-LC-Ad1 CTRP2 6.6821 8.073 5.4995 1.3127
NCI-H2085 GDSC2; CTRP2; CCLE 6.6841 11.5647 3.7976 8.2664
NCI-H1734 GDSC2; CTRP2 6.711 10.7155 4.2384 6.3957
Hs 229.T CCLE 6.8343 8.9662 2.3182 0.1587
HCC95 CTRP2 6.9106 12.4002 3.5564 8.8717
NCI-H2286 CTRP2; CCLE 7.0595 9.8418 4.9105 3.1262
GLC-82 CCLE 7.1445 10.1489 2.0196 0.5535
NCI-H460 GDSC2; CTRP2; CCLE 7.2947 9.6384 5.1515 1.9172
NCI-H1623 GDSC2; CTRP2 7.3098 11.3699 4.3482 5.0238
MOR/CPR CTRP2; CCLE 7.3637 8.2356 5.7623 0.0935
BEN GDSC2; CTRP2 7.3916 8.3807 5.7212 0.1468
NCI-H441 GDSC2; CTRP2; CCLE 7.4846 9.8935 5.1462 1.7391
HCC827 GDSC2; CTRP2; CCLE 7.6135 9.8771 5.2237 1.3536
NCI-H2126 CTRP2 7.8291 9.2307 5.5831 0.2514
NCI-H2291 GDSC2; CTRP2 7.9865 11.9269 4.5209 3.4831
NCI-H1435 GDSC2; CTRP2 7.9994 9.5685 5.5267 0.2984
NCI-H2023 GDSC2; CTRP2; CCLE 8.0415 9.5407 5.5534 0.2372
COLO 699 CTRP2; CCLE 8.2748 14.3995 3.5474 6.8523
NCI-H2172 GDSC2; CTRP2; CCLE 8.3253 9.7177 5.5965 0.1139
LXF 289 GDSC1; GDSC2; CTRP2 8.3596 10.4272 5.3528 0.5138
NCI-H2009 GDSC2; CTRP2; CCLE 8.48 10.3275 5.4387 0.301
NCI-H128 GDSC1 10.2981 25.5127 -3.7726 14.9647
HCC2108 CTRP2 10.5095 20.2307 2.237 8.8017
Hs 888.Lu CTRP2 5.0428 6.0192 4.9581 6.9682
⏷ Show the Full List of 227 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 2.1815 3.3686 2.0643 12.0637
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 1.0953 4.3868 0.9891 33.3197
P-STS CTRP2 2.9411 7.7661 2.0703 23.7965
SYO-1 CTRP2 4.0451 6.0502 3.861 13.9637
Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 1.862 6.0385 1.4816 29.1514
OV7 CTRP2 0.3227 4.3879 0.162 38.5845
A2780 GDSC2; CTRP2; CCLE 2.0593 3.3666 2.0578 26.5544
HEY A8 CTRP2; CCLE 2.3891 4.4899 2.3482 24.4899
Caov-4 GDSC2 2.4925 4.6921 1.8641 11.9619
JHOS-4 GDSC2; CCLE 2.5983 3.9002 2.3236 7.3273
COV434 CTRP2 2.6615 3.7132 2.6607 22.54
TOV-112D GDSC2; CTRP2; CCLE 2.7041 4.9496 2.6291 22.5078
TYK-nu GDSC2; CTRP2; CCLE 2.7119 4.1 2.7055 22.223
OVK18 GDSC2; CTRP2 2.8073 4.688 2.7691 21.6946
OV-90 GDSC2; CTRP2; CCLE 2.9256 4.806 2.8819 20.9253
OVCAR-3 GDSC2; CCLE 2.9799 4.593 2.3828 5.8472
ES-2 GDSC1; GDSC2; CCLE 3.0129 3.8835 2.7551 3.8323
OVMANA CCLE 3.0355 4.247 2.4059 3.132
TOV-21G GDSC2; CCLE 3.3082 4.5381 2.7024 3.3
OC 314 GDSC2; CTRP2; CCLE 3.3433 4.5416 3.3356 18.0209
SNU-8 CTRP2 3.4713 5.4613 3.3713 17.4845
IGROV-1 GDSC2; CTRP2; CCLE 3.5951 5.771 3.4408 16.8514
OVCAR-5 GDSC2; CTRP2 3.6408 4.8532 3.6268 16.0598
OV56 GDSC2; CTRP2 3.7062 6.0552 3.4898 16.3346
COV318 CCLE 3.7154 6.3419 1.8812 4.4966
SNU-119 CTRP2 3.7986 5.8294 3.6487 15.4814
ONCO-DG-1 CTRP2; CCLE 3.8339 5.8291 3.6872 15.235
Kuramochi GDSC1; GDSC2; CTRP2; CCLE 3.8947 5.8797 3.7412 14.8546
OAW42 GDSC2; CTRP2 3.8989 5.9299 3.7332 14.87
JHOM-1 CTRP2 3.927 6.3279 3.6504 15.0856
OVKATE GDSC2 4.0359 5.6725 2.675 2.4264
MCAS CTRP2; CCLE 4.119 6.5525 3.7853 14.0224
OVCAR-8 GDSC2; CTRP2; CCLE 4.181 6.1896 3.9694 13.16
COV362 CTRP2 4.2588 6.7928 3.8502 13.3768
JHOS-2 GDSC2; CTRP2; CCLE 4.4844 6.2 4.297 11.0545
COV644 CTRP2 4.5872 6.6023 4.2732 10.8428
Caov-3 GDSC2; CTRP2 4.6131 6.6385 4.2877 10.7143
SNU-840 CTRP2 4.7238 6.4768 4.4657 9.727
FU-OV-1 GDSC2; CTRP2; CCLE 4.7327 7.8456 3.9059 11.8885
COV504 CCLE 4.744 6.9753 2.2088 1.44
EFO-21 GDSC2; CTRP2; CCLE 4.7784 8.4234 3.6856 12.6608
OVCAR-4 GDSC1; GDSC2; CTRP2; CCLE 4.7792 7.7544 3.9941 11.4175
EFO-27 GDSC2; CTRP2; CCLE 4.9746 7.1503 4.4615 9.0556
OVTOKO GDSC2; CTRP2; CCLE 5.0154 7.3844 4.3998 9.1947
OC 316 CCLE 5.6336 7.1155 2.5258 0.1155
OC 315 CCLE 5.6851 7.181 2.5215 0.1122
OAW28 GDSC2; CTRP2 5.9593 8.8593 4.5655 6.3825
ES2 CTRP2 7.5884 8.7197 5.6748 0.1668
OVISE GDSC2; CTRP2 7.6429 9.116 5.5495 0.3937
OVSAHO CTRP2; CCLE 8.1873 10.1427 5.3884 0.5109
SK-OV-3 GDSC2; CTRP2; CCLE 8.1945 9.5541 5.606 0.1257
DOV13 GDSC2; CTRP2; CCLE 8.389 9.8856 5.5614 0.1429
RMG-I GDSC2; CTRP2 8.8308 10.7387 5.4251 0.2291
JHOC-5 CTRP2 10.0615 18.188 2.904 7.0224
⏷ Show the Full List of 50 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 4.4621 5.5849 4.4179 10.6918
Aska-SS CTRP2 4.6986 5.7469 4.645 9.1494
A-204 GDSC2; CTRP2; CCLE 0.386 4.9655 0.1269 38.4316
G-402 GDSC2; CTRP2; CCLE 0.8671 5.9401 0.4224 35.8284
G-401 GDSC2; CTRP2; CCLE 2.4427 3.6749 2.4409 24.0012
TE 441.T GDSC1; GDSC2; CTRP2 2.4572 3.8972 2.4517 23.9168
TE 617.T CTRP2; CCLE 2.5046 3.3691 2.5045 23.5829
Hs 633.T GDSC2 2.5177 3.3354 2.4405 8.4781
Rh41 GDSC2; CTRP2 2.6082 5.0381 2.5135 23.2144
SK-UT-1 GDSC1; GDSC2; CTRP2 2.6429 4.6269 2.6021 22.7989
KYM-1 GDSC1; GDSC2; CTRP2; CCLE 2.7007 3.3417 2.7007 22.2759
TTC-709 CTRP2 2.8131 4.3766 2.7981 21.5775
Rh30 GDSC2; CCLE 2.8606 4.218 2.4487 5.8582
Rh18 CTRP2 2.9102 5.1422 2.8214 21.1826
VA-ES-BJ GDSC1; GDSC2 2.933 4.65 2.3112 7.6276
EW-8 GDSC1; GDSC2 2.9342 4.8413 2.2191 8.1976
HT-1080 GDSC2; CTRP2; CCLE 2.9668 3.8904 2.9662 20.5054
BT-12 CTRP2 3.0622 4.0226 3.0613 19.8709
GCT GDSC2; CTRP2; CCLE 3.1261 4.1541 3.1242 19.4484
STS-0421 GDSC2 3.1505 5.2288 2.2221 7.4781
SW872 GDSC1; GDSC2 3.4317 5.7128 2.2167 6.6845
BT-16 CTRP2 3.4368 4.1332 3.4366 17.3729
MFH-ino GDSC1; GDSC2 3.4705 6.0453 2.082 7.4271
MES-SA GDSC2; CTRP2; CCLE 3.5199 4.8897 3.4985 16.8903
Tm87-16 CTRP2 3.5904 5.2585 3.5328 16.5444
SW684 GDSC1; GDSC2 3.5935 4.7399 2.8245 2.4421
SK-LMS-1 GDSC1; GDSC2; CTRP2; CCLE 3.7769 5.7706 3.6388 15.5838
RD GDSC2; CTRP2; CCLE 3.8822 6.6358 3.5004 15.7728
Hs 729.T CTRP2; CCLE 3.9282 6.0272 3.7396 14.7577
SW982 GDSC2; CTRP2 5.1746 5.9149 5.1272 5.9581
RKN GDSC2; CTRP2; CCLE 8.0347 9.5218 5.5576 0.2322
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 5.5776 10.7499 3.2922 12.4696
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC1; GDSC2; CTRP2; CCLE 2.4941 5.6163 2.2778 24.3977
IST-Mes2 CCLE 2.7774 4.256 2.1781 5.0404
NCI-H2452 GDSC2; CTRP2; CCLE 3.2714 5.4785 3.1517 18.8849
IST-Mes1 GDSC1; GDSC2; CTRP2; CCLE 3.4132 6.4294 3.0592 18.783
NCI-H28 GDSC2; CTRP2; CCLE 3.4997 4.8588 3.4798 17.02
MPP 89 GDSC1; GDSC2; CTRP2; CCLE 4.1685 6.3194 3.9159 13.3931
JL-1 CTRP2 4.3017 6.9359 3.8419 13.2874
ACC-MESO-1 CTRP2 7.6489 11.0986 4.6963 3.2151
NCI-H2052 GDSC2; CTRP2; CCLE 8.7716 10.5946 5.454 0.2027
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC1; GDSC2; CTRP2 2.5364 4.6656 2.4858 23.5414
PC-3 GDSC2; CCLE 3.2582 4.5844 2.6368 3.77
NCI-H660 GDSC2; CTRP2 3.3521 4.6546 3.3396 17.978
PaCa-3 CTRP2 3.6815 5.6156 3.5689 16.1291
DU145 GDSC2; CTRP2; CCLE 3.7636 5.4244 3.693 15.4355
VCaP GDSC1; GDSC2; CTRP2 3.7714 5.2821 3.7227 15.3082
22Rv1 GDSC2; CTRP2; CCLE 8.6103 11.9923 4.8387 1.7733
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; GDSC2; CTRP2; CCLE 3.4037 5.7759 3.2311 18.1904
YD-15 CTRP2 7.7497 8.8396 5.6927 0.1045
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 1.3556 2.632 1.3175 19.9267
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-39 GDSC1; GDSC2 0.8484 2.9102 0.7227 25.4705
SNU-16 GDSC1; GDSC2; CTRP2; CCLE 1.064 3.7559 1.0227 33.3164
SNU-1 GDSC1; GDSC2; CTRP2; CCLE 1.7641 4.8052 1.6439 28.921
Fu97 GDSC2; CTRP2; CCLE 2.5413 4.556 2.502 23.4703
ECC12 GDSC1; GDSC2; CTRP2 2.5761 3.8036 2.5739 23.1135
ECC10 GDSC2; CTRP2 2.5986 4.0698 2.5908 22.9823
HGC-27 GDSC2; CTRP2; CCLE 2.7258 4.0797 2.7202 22.1276
IM95 GDSC2; CTRP2; CCLE 2.8042 4.2285 2.7955 21.6158
KATO III GDSC2; CTRP2 2.8805 7.5012 2.1075 23.8385
RF-48 GDSC1; GDSC2 2.9078 4.2883 2.4615 6.7847
AZ-521 CCLE 2.925 4.6008 2.1363 4.87
GSS CTRP2 2.9355 4.1168 2.9322 20.7231
TGBC11TKB GDSC2 3.0824 4.3389 2.6023 5.304
GCIY GDSC1; GDSC2; CCLE 3.1416 4.5522 2.5507 4.5254
TMK-1 GDSC2 3.1688 4.8174 2.443 6.0267
SH-10-TC CTRP2; CCLE 3.2139 4.3134 3.2104 18.8687
SK-GT-2 GDSC2 3.3059 5.9022 2.0184 8.2971
RERF-GC-1B GDSC2; CCLE 3.3522 5.3183 2.3488 5.0584
MKN28 GDSC2 3.3736 5.9055 2.073 7.7568
SNU-216 CTRP2 3.376 5.1039 3.3248 17.9505
SCH GDSC1; GDSC2 3.3887 6.0065 2.0349 7.9539
NCI-N87 GDSC2; CTRP2; CCLE 3.4617 5.7445 3.3017 17.76
HuG1-N CTRP2 3.4718 5.212 3.4126 17.3398
SNU-5 GDSC1; GDSC2; CTRP2 3.4859 6.2782 3.1851 18.1059
MKN7 GDSC2; CTRP2; CCLE 3.4916 5.7894 3.3237 17.5886
NUGC-4 GDSC2; CTRP2; CCLE 3.5287 4.8251 3.5123 16.815
OCUM-1 GDSC2; CCLE 3.5708 5.3674 2.4985 3.7754
SNU-620 CTRP2 3.7801 4.3678 3.78 15.0854
SNU-601 CTRP2 3.7829 5.3569 3.7243 15.2656
Hs 746.T GDSC2; CTRP2; CCLE 3.8997 5.6757 3.7932 14.655
MKN74 CTRP2; CCLE 3.9337 5.9644 3.7622 14.6596
MKN1 GDSC2; CTRP2 4.0389 5.424 3.9886 13.5317
AGS GDSC2; CTRP2 4.0597 6.5983 3.7054 14.4925
LMSU CTRP2 4.6589 11.6801 2.0024 19.5703
BGC-823 CCLE 4.784 7.1573 2.1524 1.6271
KE-39 CTRP2; CCLE 5.6052 9.7481 3.8149 10.2494
GSU CTRP2 6.9432 7.418 5.8929 0.0223
SNU-668 CTRP2 7.4467 13.0471 3.6317 7.7065
MKN45 GDSC2; CTRP2; CCLE 7.4899 12.2011 4.0715 5.8763
NUGC-3 GDSC2; CTRP2; CCLE 8.0931 9.7874 5.4833 0.3484
23132/87 GDSC2; CTRP2 8.1004 9.7035 5.5172 0.282
SNU-719 CTRP2 8.3366 13.1878 4.1541 4.453
SNG-M GDSC2; CTRP2; CCLE 4.2156 6.528 3.8983 13.3199
SNU-1077 CTRP2 4.5077 6.7175 4.1451 11.5537
SNU-685 CTRP2 6.1173 10.2616 3.9963 8.465
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CTRP2; CCLE 0.1463 7.9554 -0.9996 41.6609
CGTH-W-1 GDSC1; GDSC2; CTRP2 1.9012 10.9996 -0.3812 34.3096
IHH-4 GDSC2 2.4102 3.2005 2.3573 9.4245
B-CPAP GDSC2; CTRP2; CCLE 2.4695 3.7173 2.4674 23.8233
KMH-2 GDSC2 2.5312 4.5277 1.9782 11.1251
HTC-C3 GDSC2 2.83 4.2172 2.419 7.3285
K5 GDSC1; GDSC2 3.0589 4.43 2.5359 5.7985
ASH-3 GDSC2 3.067 4.0964 2.7061 4.7098
8305C GDSC2; CTRP2; CCLE 3.3524 4.425 3.3485 17.9473
8505C GDSC2; CTRP2; CCLE 3.3821 5.4014 3.2858 18.0656
TT GDSC2; CTRP2 3.6475 5.4548 3.5628 16.258
FTC-238 CTRP2 3.6495 5.8371 3.4843 16.528
CAL-62 GDSC2; CTRP2 4.1746 5.4769 4.1261 12.6216
ML-1 [Human leukemia] GDSC2; CTRP2 4.2347 6.5736 3.9032 13.2464
WRO GDSC2 4.5839 6.5456 2.6006 1.951
TT2609-C02 GDSC2; CTRP2; CCLE 4.9016 7.6794 4.1515 10.4774
FTC-133 GDSC2; CTRP2 5.0357 9.1051 3.6093 12.3581
BHT-101 GDSC2; CTRP2 8.1357 9.7332 5.5202 0.2655
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Ca9-22 GDSC2 1.1977 3.847 0.8417 23.2167
BB30-HNC GDSC1; GDSC2 1.266 3.3343 1.0748 21.637
HSC-2 GDSC2; CTRP2; CCLE 2.279 3.0553 2.279 25.0857
HO-1-u-1 GDSC2 2.585 4.1146 2.2181 9.4762
BB49-HNC GDSC1; GDSC2 2.7032 5.3846 1.7384 11.9768
LB771-HNC GDSC1; GDSC2 2.7336 4.551 2.1677 9.2194
PCI-15A GDSC2 2.7626 3.9808 2.4589 7.343
SAS GDSC2 2.7634 4.2344 2.3449 8.0274
BICR 10 GDSC2 2.8004 3.9648 2.5046 6.922
KON GDSC2 2.8063 5.9267 1.5683 12.681
NCI-H3118 GDSC2 2.8088 4.614 2.2107 8.6847
PCI-06A GDSC2 2.8902 4.7161 2.239 8.2241
JHU-011 GDSC2 2.8914 4.4075 2.3888 7.2915
FaDu GDSC2; CTRP2; CCLE 2.9004 4.569 2.8766 21.0258
CAL-27 GDSC2; CTRP2; CCLE 2.9191 4.3322 2.9092 20.8542
PE/CA-PJ15 GDSC2; CTRP2 3.0251 5.0725 2.9548 20.3535
SKN-3 GDSC2 3.0421 4.9523 2.2632 7.5639
KOSC-2 GDSC2 3.0485 6.049 1.7243 10.9277
HO-1-N-1 GDSC2 3.063 4.3333 2.587 5.4651
OSC-19 GDSC2 3.107 4.637 2.4777 6.0051
HSC-4 GDSC2; CTRP2 3.1155 4.0454 3.1147 19.5153
PCI-04B GDSC2 3.1471 5.3576 2.155 7.9124
PCI-30 GDSC2 3.176 4.3157 2.6987 4.3915
SAT [Human HNSCC] GDSC2 3.189 5.1189 2.3104 6.8012
SCC-4 GDSC2; CTRP2 3.2877 5.2571 3.2085 18.6352
JHU-029 GDSC2 3.3107 6.7848 1.5811 11.0253
SCC-15 GDSC1; GDSC2 3.3529 6.1438 1.9367 8.6757
JHU-022 GDSC2 3.4817 5.1328 2.5459 4.4679
BICR 78 GDSC2 3.5205 5.2731 2.5065 4.6135
OSC-20 GDSC2 3.7328 5.7349 2.4384 4.5066
SCC-25 GDSC2; CTRP2; CCLE 3.7432 5.8432 3.585 15.8798
CAL-33 GDSC2; CTRP2 3.8287 5.2706 3.7854 14.908
UPCI-SCC-090 GDSC2 3.9008 6.9817 1.9492 7.1387
DOK GDSC2 3.9275 6.0782 2.41 4.2325
YD-8 CTRP2 4.2369 6.1267 4.0487 12.7027
PE/CA-PJ34 (clone C12) CTRP2 4.3692 6.6359 4.0264 12.3967
PE/CA-PJ49 CTRP2 4.5238 6.1741 4.3477 10.7512
SNU-1214 CTRP2 4.6107 7.3108 4.0157 11.7709
PE/CA-PJ41 (clone D2) CTRP2 4.7087 6.3373 4.4974 9.6525
BICR 16 CTRP2 4.9514 5.9231 4.8823 7.5209
SCC-9 GDSC2; CTRP2; CCLE 5.0468 6.8268 4.6743 8.0286
BICR 6 CTRP2 5.1452 6.3391 4.9693 6.6239
BICR 18 CTRP2 5.2028 8.2127 4.1982 9.5531
BICR 22 GDSC2; CTRP2 5.3446 5.9737 5.2988 4.8207
BICR 31 GDSC2; CTRP2 6.2048 8.1609 5.1166 3.6009
YD-10B CTRP2 7.5382 11.7436 4.3229 4.8073
SNU-1076 CTRP2 7.6942 8.893 5.6531 0.1725
BICR 56 CTRP2 7.7653 10.6545 4.9664 2.0949
SNU-1066 CTRP2 7.9249 12.1718 4.37 4.1266
Detroit 562 GDSC2; CTRP2; CCLE 8.0271 9.9536 5.3921 0.5791
SNU-46 CTRP2 8.1613 10.0097 5.428 0.4352
Hs 840.T CCLE 8.2297 11.0727 2.0918 0.1935
BHY GDSC2; CTRP2 8.5818 10.3176 5.4811 0.2078
SNU-1041 CTRP2 8.6237 10.4508 5.4495 0.2437
HSC-3 GDSC2; CTRP2 8.708 17.0515 2.5713 9.9478
SNU-899 CTRP2 11.8926 20.6933 2.8281 5.4265
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
UM-UC-1 CTRP2 2.2602 3.5485 2.2584 25.2168
KU-19-19 GDSC2; CTRP2 2.4737 4.8959 2.3905 24.0708
SCaBER CTRP2; CCLE 2.5797 3.4189 2.5796 23.0828
JMSU-1 CTRP2; CCLE 2.581 4.1882 2.5683 23.116
UM-UC-3 GDSC2; CTRP2; CCLE 2.8011 4.3536 2.7869 21.655
U-BLC1 CTRP2 2.9169 4.1655 2.9123 20.851
639V GDSC2; CTRP2; CCLE 3.2317 4.0913 3.2311 18.7406
VM-CUB-1 CTRP2 3.233 5.2197 3.1557 18.993
HT-1197 GDSC2; CTRP2; CCLE 3.2602 4.2229 3.2587 21.4061
BC-3C CTRP2 3.3946 5.3887 3.3016 17.9713
5637 GDSC2; CTRP2; CCLE 3.407 5.455 3.303 17.9266
SW780 GDSC2; CCLE 3.4705 5.4298 2.3891 4.5705
253J-BV CTRP2 3.7698 5.21 3.7303 15.2872
BFTC-905 GDSC2; CTRP2 3.9255 5.0593 3.9088 14.1725
RT-112 GDSC2; CTRP2; CCLE 4.1168 6.4293 3.8243 13.8839
TCCSUP GDSC2; CTRP2; CCLE 4.1181 6.146 3.9136 13.5521
KMBC-2 CTRP2; CCLE 4.4424 5.7511 4.3666 10.9332
647V GDSC2; CTRP2 4.4461 6.3887 4.1953 11.5426
CAL-29 GDSC2; CTRP2 4.4875 6.1904 4.3033 11.0222
T24 GDSC2; CTRP2; CCLE 4.536 8.9737 3.1896 15.2514
HT-1376 GDSC2; CTRP2; CCLE 4.6998 7.2335 4.1412 11.0414
J82 GDSC2; CTRP2; CCLE 4.875 6.0743 4.7599 8.194
SW1710 GDSC2; CTRP2 4.9165 7.3925 4.2955 9.8642
RT-4 GDSC2; CTRP2; CCLE 8.581 10.173 5.5313 0.1435
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NEC8 GDSC1; GDSC2 1.0469 3.8237 0.686 24.7413
NT2-D1 GDSC1; GDSC2 1.6306 2.8131 1.586 17.2009
C-33 A GDSC2 1.6946 3.403 1.5231 17.2382
TC-YIK GDSC2 1.9009 3.1211 1.821 14.6752
NCC-IT GDSC1; GDSC2 1.967 3.9464 1.6357 15.4107
JAR GDSC1; GDSC2 2.1728 3.5917 1.9851 12.5417
PA-1 GDSC2 2.3462 4.8892 1.6275 13.9436
ACC-OV7 GDSC2 2.4667 6.2705 1.0858 16.7678
OV17R GDSC2 2.5695 4.5625 2.0005 10.8456
C-4-I GDSC2 2.5809 4.1033 2.2188 9.4879
KGN GDSC1; GDSC2 2.8583 4.0844 2.5086 6.6779
OVCA433 GDSC2 2.8954 4.8405 2.1834 8.5525
JEG-3 GDSC2 2.9055 5.2308 2.0016 9.6533
CAL-39 GDSC2 2.9301 4.2668 2.4933 6.5092
DSH1 GDSC1; GDSC2 3.0075 4.754 2.3295 7.2613
HEY GDSC2 3.0394 5.1943 2.141 8.3404
UWB1.289 GDSC2 3.0765 5.7502 1.8977 9.7531
BPH-1 GDSC2 3.0888 5.1919 2.1862 7.8983
SKN GDSC2 3.1438 4.5323 2.5626 5.352
OVCA420 GDSC2 3.1539 4.7047 2.4859 5.8028
PWR-1E GDSC2 3.2307 4.9674 2.422 5.969
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 3.247 4.7832 2.5279 5.2493
SiSo GDSC2 3.3214 5.3152 2.3248 6.3146
SKG-IIIa GDSC2 3.3255 4.733 2.6194 4.4376
SW954 GDSC1; GDSC2 3.3559 5.4022 2.31 6.3089
SiHa GDSC2 3.3841 5.5202 2.2741 6.4552
ME-180 GDSC2 3.3864 6.0576 2.0074 8.1341
SW962 GDSC1; GDSC2 3.3981 5.534 2.2787 6.3868
LB831-BLC GDSC1; GDSC2 3.4309 5.381 2.3818 5.6431
SW756 GDSC2 3.4524 8.3164 0.9326 14.522
HEC-1 GDSC2 3.4546 5.7261 2.2285 6.5464
JHOS-3 GDSC2 3.4939 5.2786 2.483 4.8325
MS751 GDSC2 3.5576 5.9441 2.2017 6.4358
Ca Ski GDSC2 3.7669 5.9438 2.3608 4.9073
DoTc2 4510 GDSC2 3.9159 6.1637 2.3605 4.5619
OVMIU GDSC2 3.9482 6.1962 2.3673 4.4475
PEO1 GDSC2 4.2075 6.5158 2.389 3.7733
HT-3 GDSC2 4.5214 7.2094 2.2636 3.9097
HeLa GDSC2; CTRP2 7.2733 12.5171 3.7663 7.4306
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sorafenib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [24]
Metreleptin DM1NOEK Moderate Increased metabolism of Sorafenib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [25]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Sorafenib and Ivosidenib. Acute myeloid leukaemia [2A60] [26]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Midostaurin. Acute myeloid leukaemia [2A60] [27]
Idarubicin DMM0XGL Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [28]
Daunorubicin DMQUSBT Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [28]
Arn-509 DMT81LZ Moderate Increased metabolism of Sorafenib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [25]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Gilteritinib. Acute myeloid leukaemia [2A60] [29]
Mitotane DMU1GX0 Moderate Increased metabolism of Sorafenib caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [25]
Framycetin DMF8DNE Moderate Altered absorption of Sorafenib due to GI flora changes caused by Framycetin. Alcoholic liver disease [DB94] [24]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Galantamine. Alzheimer disease [8A20] [27]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Rivastigmine. Alzheimer disease [8A20] [27]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Donepezil. Alzheimer disease [8A20] [27]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Sorafenib and Metronidazole. Amoebiasis [1A36] [24]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Sorafenib and Ivabradine. Angina pectoris [BA40] [30]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Sorafenib and Bepridil. Angina pectoris [BA40] [27]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Sorafenib and Dronedarone. Angina pectoris [BA40] [27]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Sorafenib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [31]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Sorafenib caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [32]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [27]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Promazine. Appearance/behaviour symptom [MB23] [27]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Cilostazol. Arterial occlusive disease [BD40] [27]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Voriconazole. Aspergillosis [1F20] [27]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Posaconazole. Aspergillosis [1F20] [27]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Levalbuterol. Asthma [CA23] [33]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Terbutaline. Asthma [CA23] [34]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Pirbuterol. Asthma [CA23] [34]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Salbutamol. Asthma [CA23] [33]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Formoterol. Asthma [CA23] [34]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [30]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Ofloxacin. Bacterial infection [1A00-1C4Z] [27]
Oritavancin DM28D05 Moderate Increased metabolism of Sorafenib caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [27]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Clarithromycin. Bacterial infection [1A00-1C4Z] [27]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Sorafenib and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [27]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Sorafenib and Sparfloxacin. Bacterial infection [1A00-1C4Z] [35]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Gemifloxacin. Bacterial infection [1A00-1C4Z] [27]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Norfloxacin. Bacterial infection [1A00-1C4Z] [27]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Levofloxacin. Bacterial infection [1A00-1C4Z] [27]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Lomefloxacin. Bacterial infection [1A00-1C4Z] [27]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Telithromycin. Bacterial infection [1A00-1C4Z] [27]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Retigabine. Behcet disease [4A62] [27]
Pexidartinib DMS2J0Z Major Decreased metabolism of Sorafenib caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [36]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Loperamide. Bowel habit change [ME05] [37]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Eribulin. Breast cancer [2C60-2C6Y] [27]
Talazoparib DM1KS78 Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [38]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Lapatinib. Breast cancer [2C60-2C6Y] [27]
Tucatinib DMBESUA Moderate Decreased metabolism of Sorafenib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Tamoxifen. Breast cancer [2C60-2C6Y] [27]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Sorafenib and Toremifene. Breast cancer [2C60-2C6Y] [27]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Bosutinib. Breast cancer [2C60-2C6Y] [27]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Sorafenib and Sotalol. Cardiac arrhythmia [BC9Z] [27]
Secobarbital DM14RF5 Moderate Increased metabolism of Sorafenib caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [25]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [40]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [34]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Salmeterol. Chronic obstructive pulmonary disease [CA22] [34]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Indacaterol. Chronic obstructive pulmonary disease [CA22] [34]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Arformoterol. Chronic obstructive pulmonary disease [CA22] [34]
Fidaxomicin DMFP6MV Minor Decreased clearance of Sorafenib due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [24]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Sorafenib and Anisindione. Coagulation defect [3B10] [41]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Sorafenib caused by Irinotecan mediated inhibition of UGT. Colorectal cancer [2B91] [25]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Oxaliplatin. Colorectal cancer [2B91] [27]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Isoproterenol. Conduction disorder [BC63] [33]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Halothane. Corneal disease [9A76-9A78] [27]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Propofol. Corneal disease [9A76-9A78] [42]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Sevoflurane. Corneal disease [9A76-9A78] [27]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Probucol. Coronary atherosclerosis [BA80] [27]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Clofazimine. Crohn disease [DD70] [43]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Sorafenib and Pasireotide. Cushing syndrome [5A70] [27]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Osilodrostat. Cushing syndrome [5A70] [27]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Sorafenib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [44]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Sertraline. Depression [6A70-6A7Z] [27]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Trimipramine. Depression [6A70-6A7Z] [27]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Imipramine. Depression [6A70-6A7Z] [27]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Fluoxetine. Depression [6A70-6A7Z] [27]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Nortriptyline. Depression [6A70-6A7Z] [27]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Clomipramine. Depression [6A70-6A7Z] [27]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Amoxapine. Depression [6A70-6A7Z] [27]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Doxepin. Depression [6A70-6A7Z] [27]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Maprotiline. Depression [6A70-6A7Z] [27]
Griseofulvin DMK54YG Moderate Increased metabolism of Sorafenib caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [25]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [27]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Sorafenib and Deutetrabenazine. Dystonic disorder [8A02] [45]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Sorafenib and Ingrezza. Dystonic disorder [8A02] [46]
Primidone DM0WX6I Moderate Increased metabolism of Sorafenib caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Felbamate DM1V5ZS Moderate Increased metabolism of Sorafenib caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Sorafenib caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Cenobamate DM8KLU9 Moderate Increased metabolism of Sorafenib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Sorafenib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Rufinamide DMWE60C Moderate Increased metabolism of Sorafenib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Phenobarbital DMXZOCG Moderate Increased metabolism of Sorafenib caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Carbamazepine DMZOLBI Moderate Increased metabolism of Sorafenib caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Sorafenib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Cannabidiol. Epileptic encephalopathy [8A62] [30]
Tazemetostat DMWP1BH Moderate Increased metabolism of Sorafenib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [25]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Pentamidine. Fungal infection [1F29-1F2F] [27]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Ketoconazole. Fungal infection [1F29-1F2F] [27]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Sorafenib and Cisapride. Gastro-oesophageal reflux disease [DA22] [27]
Ripretinib DM958QB Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [24]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Sunitinib. Gastrointestinal stromal tumour [2B5B] [27]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Sorafenib caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [25]
Rifampin DMA8J1G Moderate Increased metabolism of Sorafenib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [44]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of Sorafenib caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [47]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [27]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Sorafenib and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [48]
Dolutegravir DMCZGRE Minor Decreased metabolism of Sorafenib caused by Dolutegravir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [49]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Sorafenib and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [50]
Etravirine DMGV8QU Moderate Increased metabolism of Sorafenib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [27]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [27]
Maraviroc DMTL94F Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [51]
Raltegravir DMYURI6 Minor Decreased metabolism of Sorafenib caused by Raltegravir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [52]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Sorafenib and Mipomersen. Hyper-lipoproteinaemia [5C80] [53]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Sorafenib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [27]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Sorafenib and BMS-201038. Hyper-lipoproteinaemia [5C80] [54]
Aliskiren DM1BV7W Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [27]
Tolvaptan DMIWFRL Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [55]
Lesinurad DMUR64T Moderate Increased metabolism of Sorafenib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [25]
Berotralstat DMWA2DZ Major Decreased clearance of Sorafenib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [56]
Amobarbital DM0GQ8N Moderate Increased metabolism of Sorafenib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Sorafenib caused by ITI-007 mediated inhibition of UGT. Insomnia [7A00-7A0Z] [57]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Polyethylene glycol. Irritable bowel syndrome [DD91] [30]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Phenolphthalein. Irritable bowel syndrome [DD91] [27]
Naloxegol DML0B41 Minor Decreased metabolism of Sorafenib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [58]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Methotrexate. Leukaemia [2A60-2B33] [30]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Sorafenib and Crizotinib. Lung cancer [2C25] [59]
Brigatinib DM7W94S Moderate Increased metabolism of Sorafenib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [25]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Sorafenib and Ceritinib. Lung cancer [2C25] [27]
PF-06463922 DMKM7EW Moderate Increased metabolism of Sorafenib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [25]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Sorafenib and Osimertinib. Lung cancer [2C25] [60]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Sorafenib and Selpercatinib. Lung cancer [2C25] [30]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Sorafenib and Lumefantrine. Malaria [1F40-1F45] [24]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Sorafenib and Halofantrine. Malaria [1F40-1F45] [61]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Sorafenib and Chloroquine. Malaria [1F40-1F45] [62]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Sorafenib and Hydroxychloroquine. Malaria [1F40-1F45] [62]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Quinine. Malaria [1F40-1F45] [27]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Primaquine. Malaria [1F40-1F45] [27]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [30]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [63]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Idelalisib. Mature B-cell leukaemia [2A82] [64]
GDC-0199 DMH0QKA Major Decreased clearance of Sorafenib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [24]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Clofarabine. Mature B-cell lymphoma [2A85] [65]
Arry-162 DM1P6FR Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Arry-162. Melanoma [2C30] [24]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Sorafenib and Vemurafenib. Melanoma [2C30] [27]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and LGX818. Melanoma [2C30] [27]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Sorafenib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [30]
Exjade DMHPRWG Moderate Increased metabolism of Sorafenib caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [25]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Sorafenib and Panobinostat. Multiple myeloma [2A83] [66]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Sorafenib and Thalidomide. Multiple myeloma [2A83] [24]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Sorafenib and Siponimod. Multiple sclerosis [8A40] [24]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Sorafenib and Fingolimod. Multiple sclerosis [8A40] [27]
Rifabutin DM1YBHK Moderate Increased metabolism of Sorafenib caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [25]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Romidepsin. Mycosis fungoides [2B01] [27]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Sorafenib and Nilotinib. Myeloproliferative neoplasm [2A20] [27]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Dasatinib. Myeloproliferative neoplasm [2A20] [27]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Sorafenib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [67]
Modafinil DMYILBE Moderate Increased metabolism of Sorafenib caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [25]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Prochlorperazine. Nausea/vomiting [MD90] [27]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Sorafenib and Dolasetron. Nausea/vomiting [MD90] [27]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Ondansetron. Nausea/vomiting [MD90] [27]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Sorafenib and Levomethadyl Acetate. Opioid use disorder [6C43] [30]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Lofexidine. Opioid use disorder [6C43] [27]
Olaparib DM8QB1D Moderate Increased metabolism of Sorafenib caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [24]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Rucaparib. Ovarian cancer [2C73] [27]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Dextropropoxyphene. Pain [MG30-MG3Z] [27]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Buprenorphine. Pain [MG30-MG3Z] [27]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Triclabendazole. Parasitic worm infestation [1F90] [27]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Pimavanserin. Parkinsonism [8A00] [68]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Famotidine. Peptic ulcer [DA61] [24]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Sorafenib and Macimorelin. Pituitary gland disorder [5A60-5A61] [69]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Sorafenib and Lefamulin. Pneumonia [CA40] [70]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Ritodrine. Preterm labour/delivery [JB00] [34]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Degarelix. Prostate cancer [2C82] [30]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Nilutamide. Prostate cancer [2C82] [30]
Enzalutamide DMGL19D Moderate Increased metabolism of Sorafenib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [25]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Flutamide. Prostate cancer [2C82] [30]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Relugolix. Prostate cancer [2C82] [30]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Bicalutamide. Prostate cancer [2C82] [30]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Levomepromazine. Psychotic disorder [6A20-6A25] [27]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Fluphenazine. Psychotic disorder [6A20-6A25] [27]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Triflupromazine. Psychotic disorder [6A20-6A25] [27]
Bosentan DMIOGBU Moderate Increased metabolism of Sorafenib caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [25]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Sorafenib and Gatifloxacin. Respiratory infection [CA07-CA4Z] [71]
Dexamethasone DMMWZET Moderate Increased metabolism of Sorafenib caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [25]
Nafcillin DMN9RPO Moderate Increased metabolism of Sorafenib caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [25]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Sorafenib and Leflunomide. Rheumatoid arthritis [FA20] [27]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Quetiapine. Schizophrenia [6A20] [27]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Sorafenib and Mesoridazine. Schizophrenia [6A20] [27]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Sorafenib and Thioridazine. Schizophrenia [6A20] [27]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Aripiprazole. Schizophrenia [6A20] [24]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Sorafenib and Iloperidone. Schizophrenia [6A20] [27]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Paliperidone. Schizophrenia [6A20] [27]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Sorafenib and Haloperidol. Schizophrenia [6A20] [27]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Perphenazine. Schizophrenia [6A20] [27]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Chlorpromazine. Schizophrenia [6A20] [27]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Trifluoperazine. Schizophrenia [6A20] [27]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Risperidone. Schizophrenia [6A20] [27]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Sorafenib and Amisulpride. Schizophrenia [6A20] [72]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Asenapine. Schizophrenia [6A20] [27]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Sorafenib and Pimozide. Schizophrenia [6A20] [30]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Vardenafil. Sexual dysfunction [HA00-HA01] [27]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Sorafenib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [32]
PDX-101 DM6OC53 Moderate Decreased metabolism of Sorafenib caused by PDX-101 mediated inhibition of UGT. Solid tumour/cancer [2A00-2F9Z] [73]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [30]
Armodafinil DMGB035 Moderate Increased metabolism of Sorafenib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [25]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Sorafenib and LEE011. Solid tumour/cancer [2A00-2F9Z] [27]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [30]
Taxol DMUOT9V Moderate Decreased metabolism of Sorafenib caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [30]
Doxorubicin DMVP5YE Moderate Decreased clearance of Sorafenib due to the transporter inhibition by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [30]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [27]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Sorafenib and Naltrexone. Substance abuse [6C40] [74]
Warfarin DMJYCVW Moderate Increased risk of bleeding by the combination of Sorafenib and Warfarin. Supraventricular tachyarrhythmia [BC81] [41]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Sorafenib and Adenosine. Supraventricular tachyarrhythmia [BC81] [27]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Sorafenib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [75]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Lenvatinib. Thyroid cancer [2D10] [27]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Sorafenib and Cabozantinib. Thyroid cancer [2D10] [30]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Sorafenib and Papaverine. Tonus and reflex abnormality [MB47] [76]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Tacrolimus. Transplant rejection [NE84] [27]
Dapagliflozin DM28UJG Minor Decreased metabolism of Sorafenib caused by Dapagliflozin mediated inhibition of UGT. Type 2 diabetes mellitus [5A11] [77]
Elagolix DMB2C0E Moderate Increased metabolism of Sorafenib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [25]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Astemizole. Vasomotor/allergic rhinitis [CA08] [27]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [27]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Sorafenib and Procainamide. Ventricular tachyarrhythmia [BC71] [27]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Propafenone. Ventricular tachyarrhythmia [BC71] [27]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Sorafenib and Flecainide. Ventricular tachyarrhythmia [BC71] [27]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Sorafenib and Amiodarone. Ventricular tachyarrhythmia [BC71] [27]
⏷ Show the Full List of 226 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sorafenib 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Sorafenib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
7 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
8 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
9 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
10 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
11 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
12 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
13 Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
14 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
15 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
16 Drug Interactions Flockhart Table
17 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
18 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
19 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005 Oct 21;280(42):35217-27. doi: 10.1074/jbc.M506551200. Epub 2005 Aug 18.
20 Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
21 The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
22 Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008 Oct;7(10):1648-62. doi: 10.4161/cbt.7.10.6623. Epub 2008 Oct 12.
23 The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.
24 Cerner Multum, Inc. "Australian Product Information.".
25 Product Information. Nexavar (sorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
26 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
27 Canadian Pharmacists Association.
28 Multum Information Services, Inc. Expert Review Panel.
29 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
32 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
33 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
34 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
35 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
36 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
37 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
38 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
40 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
41 Laber DA, Mushtaq M "Compassionate use of sorafenib in patients with advanced renal cell cancer." Clin Genitourin Cancer 7 (2009): 34-8. [PMID: 19213666]
42 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
43 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
44 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
45 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
46 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
47 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
48 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
49 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
50 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
51 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
52 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
53 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
54 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
55 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
56 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
57 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
58 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
59 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
61 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
62 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
63 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
64 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
65 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
66 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
67 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
68 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
69 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
70 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
71 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
72 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
73 Product Information. Beleodaq (belinostat). Spectrum Pharmaceuticals Inc, Irvine, CA.
74 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
75 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
76 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
77 Product Information. Farxiga (dapagliflozin). Bristol-Myers Squibb, Princeton, NJ.